Podcasts about Phase

In the year following the experience with King Sauvage, the seasons change and the knights experience unique events, and Sir Queegan may shift the future of the realm. For a limited time, save 15% on all Pendragon products with code "PENCANNON3" at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://chaosium.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Watch the video here: ⁠⁠⁠https://youtu.be/rq8i_SEq76Y⁠ Access ad-free episodes, exclusive podcasts, and more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠jointhenaish.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Come see us LIVE in a city near you at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.glasscannonnetwork.com/tour⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

What if a self-taught coder and waiter became one of the most active healthcare venture capitalists in the country - and could teach you everything about reinventing yourself, embracing the incubation period, and finding massive opportunity in the chaos everyone else is running from? Join Nick Lamagna on The A Game Podcast: Real Estate Investing For Entrepreneurs for one of the most raw, real, and inspiring conversations we've had - Marcus Whitney, co-founder and CEO of Jumpstart Health Investors, 3x IBJJF Masters World Champion, soccer team co-owner, podcast host, hip hop head, and creative rebel who went from broke waiter in Nashville to venture capitalist disrupting the entire healthcare industry. This isn't just a business episode - it's a masterclass on identity, reinvention, critical thinking, and what it really means to build a life worth living on your own terms, whether you're in the grind, on the mat, or in the middle of figuring out what the next chapter looks like. Whether you're an entrepreneur trying to raise capital, a Jiu Jitsu competitor questioning your next move, a real estate investor looking for your edge, or just someone trying to figure out who they are when the title gets stripped away - this conversation will change the way you think about failure, freedom, and what it actually means to bring your A Game. Marcus went from dropping out of college and showing up to a restaurant in uniform asking for a job on the spot, to building, scaling, and selling multiple companies and running one of the most active early-stage healthcare VC firms in the US. Now he's opening up about the lessons, the losses, and the season of life nobody talks about - the incubation period. While most people only talk about the climb, Marcus breaks down the real game: ✅ Why standing still is the riskiest move you can make in today's economy - and what entrepreneurship as "full contact economics" really means ✅ How to separate your identity from your achievements so failure never has the power to break you ✅ The difference between the Hustler and the Hacker - and why you need both to create outsized performance in business and in life ✅ What waiting tables taught him about people skills that no MBA program ever could ✅ Why the incubation period isn't failure - it's the most important season of growth most people never give themselves permission to experience ✅ How surrounding yourself with the right people (and cutting back on the wrong ones) is the single biggest lever you can pull for your future ✅ Why hope is the most underrated weapon an entrepreneur has - and how to use it to survive the seasons when nothing seems to be working ✅ What Jiu Jitsu, venture capital, and going back to white belt in Mexico City all have in common + more Connect with Marcus: www.marcuswhitney.com Marcus Whitney on Instagram Marcus Whitney on Facebook Marcus Whitney on YouTube Marcus Whitney on LinkedIn Marcus Whitney on Twitter   Connect with Jumpstart Foundry: www.jsf.co Jumpstart Foundry on Instagram Jumpstart Foundry on Facebook Jumpstart Foundry on YouTube Jumpstart Foundry on LinkedIn Jumpstart Foundry on TikTok Jumpstart Foundry on Twitter   Connect with Jumpstart Health Ecosystem: Jumpstart Nova Jumpstart Health Investors Jumpstart Capital Jumpstart Insight   Connect with Nashville Soccer Club: www.nashvillesc.com Nashville Soccer Club on Instagram Nashville Soccer Club on Facebook Nashville Soccer Club on YouTube Nashville Soccer Club on LinkedIn Nashville Soccer Club on TikTok Nashville Soccer Club on Twitter --- Connect with Nick Lamagna www.nicknicknick.com Text Nick (516)540-5733 Connect on ALL Social Media and Podcast Platforms Here FREE Checklist on how to bring more value to your buyers

I taught debt freedom for 15 years. I was wrong about one thing.Getting out of debt is not the finish line. It never was.I sat in my apartment — 100% debt free for the first time in my adult life — and felt completely lost. No wealth plan. No investment strategy. No legacy framework. Just zero debt and zero direction.Nobody taught me what came next. Not my school. Not my family. Not the financial system. And that silence cost me years.This episode is for everyone who crossed the finish line and felt empty instead of full. For everyone working toward debt freedom right now, wondering "then what?" For every parent doing better than their parents did — but not sure if it's going to be enough for their kids.Here's what I break down:- Why debt freedom is the starting line, not the destination- The 3 Phases of Financial Freedom (and why most people never make it past Phase 1)- The AO Legacy Framework — Protect, Grow, Transfer- Why getting out of debt with a survival mindset will sabotage your wealth every single time- What wealthy families are doing that nobody in our community is talking about- If you build it and don't transfer it, it dies with you.Your kids deserve better than starting at zero. This conversation is how we change that.Get the book: https://www.anthonyoneal.com/bookDebt Relief Resource: https://www.anthonyoneal.com/debtreliefABOUT ANTHONY ONEAL:Anthony O'Neal is a nationally bestselling author, speaker, and host of The Table with Anthony O'Neal. He holds a Bachelor of Science in Finance & Banking and is a professor of Consumer Economics at Virginia Union University. Since 2014, he's helped millions of people get out of debt, build wealth, and break generational poverty. His mission is to help you maximize your income, eliminate debt, and create a life of freedom and legacy.

Lisa Woodruff is the founder of Organize 365 and author of multiple books, most recently Escaping Quicksand. Sarah always loves her ideas about planning and time, and in today's episode they chat overcoming overwhelm, but through the lens of planning. You can find more from Lisa at organize365.com in addition to @organize365 on Instagram.Resources Mentioned from Lisa: How I divide my year into thirds episode 143 https://organize365.com/podcast/my-three-new-years/The 10 filters I use to plan my week episode 704https://organize365.com/podcast/704-the-10-filters-i-use-to-plan-my-week/The 15-minute pivot from reactive to proactive planning https://organize365.com/pivot/Escaping Quicksandhttps://organize365.com/escapingquicksand/June Sponsors: IXL: Best Laid Plans listeners can get an exclusive 20% off IXL membership when they sign up today at https://www.ixl.com/plans.Green Chef: Healthy and convenient meal kits and more! Visit greenchef.com/50bestlaid and use code 50bestlaid to get 50% off your first month, then 20% off for 2 months.PrepDish: Make your menu planning so much easier! Try it free for 2 weeks by visiting prepdish.com/plans Learn more about your ad choices. Visit megaphone.fm/adchoices

This is a free preview of a paid episode. To hear more, please visit our Patreon. Ben Lindbergh and Ben Clemens banter about some suspicious variability in the ball’s behavior and whether the low-drag, high-home-run-rate times of the late 2010s have returned, Carlos Mendoza’s “departure” from the Mets, the Blue Jays’ dominance of “Phase 1” of All-Star voting, the hitters and pitchers who have most overperformed and underperformed their projections through the halfway point of the regular season, forsaking single-team fandom, platoon god Paul Goldschmidt, Dalton Rushing’s clash with Shohei Ohtani, the Pope’s audience with A.J. Pierzynski, MLB’s economic proposals, and more, plus Stat Blasts about an unusual homestand and the Nationals’ latest, not-so-greatest bullpen blowup(s). Audio intro: Kite Person, “Effectively Wild Theme” Audio outro: Ted O., “Effectively Wild Theme” Link to MLFAD scoreboard Link to bouncing ball wiki Link to Savant drag dashboard Link to ball carry analysis Link to Nathan post 1 Link to Nathan post 2 Link to Nathan post 3 Link to Nathan post 4 Link to March/April scoring Link to May scoring Link to story about May offense Link to June scoring Link to MLB/Rawlings story Link to scoring/attendance research 1 Link to scoring/attendance research 2 Link to scoring/attendance research 3 Link to scoring/attendance research 4 Link to Mets announcement tweet Link to Mets announcement post Link to MLBTR on Mendoza Link to MLBTR on Green Link to Rosenthal on Mendoza/Stearns Link to Ben L. on team turnover Link to FG playoff odds Link to Phase 1 ASG voting results Link to Sogard contest post Link to FG combined WAR leaderboard Link to 2025 trade value series Link to Dan S. on batter ZiPS movers Link to Dan S. on pitcher ZiPS movers Link to batter preseason projections Link to batter pace leaders Link to batter paces vs. projections Link to pitcher preseason projections Link to pitcher pace leaders Link to pitcher paces vs. projections Link to MLBTR on Ragans Link to Cashman on running back the roster Link to Goldschmidt tOPS+ query Link to Goldschmidt sOPS+ query Link to 1B JAWS leaders Link to Petriello on Goldschmidt Link to Other Ben’s VEB archive Link to Jensen HR off of Kimbrel Link to Rushing/Ohtani video Link to Rushing quotes Link to Rushing postgame video Link to Ohtani postgame video Link to Roberts postgame video Link to contested challenge clip Link to dugout conferences clip Link to mound conference clip Link to costly missed catch Link to Rushing bench reaction Link to Ohtani’s Smith/Rushing splits Link to Rosenthal on Pope/Pierzynski Link to Papal infallibility wiki Link to MLB proposals article Link to MLB proposals tweet Link to MLBPA response Link to article on player aging Link to aging curve research 1 Link to aging curve research 2 Link to late homestands spreadsheet Link to BP on the Phillies comebacks Link to Langs on the Phillies comebacks Link to 2026 team RP WAR Link to worst-ever team RP WAR Link to Phillies comeback gamer Link to last-strike-comebacks data Link to non-Einstein quote investigation Link to The Athletic on the Nats’ pen Link to The Athletic on the Nats’ pen again Link to Rockies comeback gamer Link to Other Ben on inherited runners Link to Stat Blast on inherited runners Link to listener emails database Link to SCG Con Link to MLBTR on Minasian/Mozeliak Link to Miz 105.5 mph story Link to fastest tracked pitches Link to Miz postgame comment Link to Miz postgame clip Sponsor Us on Patreon Give a Gift Subscription Email Us: podcast@fangraphs.com Effectively Wild Subreddit Effectively Wild Wiki Apple Podcasts Feed Spotify Feed YouTube Playlist Facebook Group Bluesky Account Twitter Account Get Our Merch! var SERVER_DATA = Object.assign(SERVER_DATA || {}); Source

Shohei Ohtani and Ernie Clement were their leagues' top vote-getters in Phase 1 of All-Star Game balloting to secure starting spots, and finalists for the other positions were announced with Phase 2 of voting beginning Monday at noon ET. Learn more about your ad choices. Visit megaphone.fm/adchoices

AJ McGowan, VP of Research and Development at Reynolds & Reynolds. He breaks down why fragmented software platforms are quietly limiting what AI can see and do, uses a service drive scenario to show how a fully connected system could surface a high-value trade opportunity in real time, and explains why Reynolds is investing in its own hardware infrastructure to make that scale. Topics: 03:25 Why Auto AI Is Different. 06:45 Real AI Vs. Gimmicks. 08:45 Why Reynolds Is Buying Hardware. 13:15 The Bloomberg Terminal For Used Cars. 17:30 What Ray Actually Does. 22:50 Where Dealers Still Find An Edge. 28:35 Why Consolidation Is Now Critical. This episode is brought to you by: 1. Matador AI - Most dealerships are losing leads in the follow-up. Matador AI fixes that. It's not generic automation. It's dealership-trained AI, built on millions of real conversations and optimized around what converts. In a thin-margin business, every conversation matters. Book your demo today and get your first month free @ here. 2. Zurich - Zurich Advisor IQ is Zurich's AI-driven training and coaching platform built to help F&I teams perform more consistently and sell more effectively — using real transaction data, not theory. By analyzing actual F&I transactions, Zurich Advisor IQ helps identify behaviors and trends influencing results, delivers actionable insights and roleplay scenarios, and gives dealership leaders visibility into performance across managers, stores and rooftops. Connect with your Zurich representative to request a demo and see how Zurich Advisor IQ can help turn F&I insight into stronger dealership performance. Discover more @ here. 3. Reynolds and Reynolds - Turn cars faster and increase profit with AutoVision, an end-to-end inventory management suite that optimizes every step of the used vehicle lifecycle. From acquisition to sale, AutoVision gives you a clear way to manage inventory. Visit  AutoVision.com for more information. Check out Car Dealership Guy's stuff: For dealers: CDG Circles ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://cdgcircles.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Industry job board ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://jobs.dealershipguy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Dealership recruiting ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.cdgrecruiting.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Fix your dealership's social media ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.trynomad.co⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Request to be a podcast guest ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.cdgguest.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For industry vendors: Advertise with Car Dealership Guy ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.cdgpartner.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Industry job board ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://jobs.dealershipguy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Request to be a podcast guest ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://www.cdgguest.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Car Dealership Guy Socials: X ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠x.com/GuyDealership⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Instagram ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠instagram.com/cardealershipguy/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ TikTok ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠tiktok.com/@guydealership⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LinkedIn ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠linkedin.com/company/cardealershipguy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Threads ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠threads.net/@cardealershipguy⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Facebook ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠facebook.com/profile.php?id=100077402857683⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Everything else ➤ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠dealershipguy.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode of our monthly series leading up to Avengers: Doomsday, Jason and Rosie spotlight confirmed returning heroes Shang-Chi and Ant-Man, along with heavily speculated additions like Doctor Strange, Monica Rambeau (aka Photon), Ms. Marvel, and more. They explore why Shang-Chi hasn’t appeared in another film in nearly six years, what roles Doctor Strange and Monica could play in Doomsday, and how likely other unconfirmed Phase 4 and 5 characters are to show up. Next, they revisit the films and TV shows released in Phases 4 and 5, along with the behind-the-scenes developments that shaped those eras, including Disney CEO leadership changes and Marvel’s pivot away from Kang and Jonathan Majors toward Doctor Doom. To close, they dig into lingering questions from unresolved plot threads, including several post-Endgame credit scenes. Follow Jason: IG & Bluesky Follow Rosie: IG & Letterboxd Follow X-Ray Vision on Instagram Join the X-Ray Vision DiscordSee omnystudio.com/listener for privacy information.

The latest Federal Reserve policy shifts and rising geopolitical tensions are reshaping the financial landscape. With Jerome Powell exiting and Kevin Warsh signaling a tighter-lipped Fed, investors face renewed market uncertainty and an end to traditional forward guidance. This episode breaks down how the ongoing Iran conflict is dictating oil prices and the timeline for interest rate cuts, while exploring why the stock market continues to offer the best risk-to-reward ratio for capital deployment.The conversation also dives into the massive economic potential of advanced AI and robotics, analyzing predictions from industry leaders regarding the automated future of the global labor market. We evaluate the current hyper-supply phase of the real estate market cycle, the potential massive liquidity injection from the upcoming Crypto Clarity Act, and the exact $5 million financial milestone needed to achieve true freedom in today's economy.KEY TOPICS DISCUSSEDFederal Reserve policy changes and the elimination of forward guidance under Kevin Warsh.Geopolitical impacts of the 60-day MOU in the Iran conflict on global oil prices.Short-term stock market corrections and interest rate cut predictions for the coming year.Institutional investments, warm water cooling, and the bullish outlook for Nvidia.SpaceX IPO lockup periods and why short-term valuation pressures exist for early retail buyers.The integration of advanced humanoid robotics into global labor markets and factory infrastructure.The upcoming US House committee hearing on the Crypto Clarity Act and its potential market impact.Phase three and four of the Mueller real estate cycle and how to acquire undervalued commercial assets.Leveraging life insurance arbitrage to invest in real estate debt funds for positive yield.KEY TAKEAWAYSThe Federal Reserve's decision to drop forward guidance removes the market's reliance on predictable rate cuts, signaling a return to historically normal, higher interest rate environments.Global oil prices remain the primary linchpin for future interest rate decisions, as energy costs directly drive producer costs and broader inflation metrics.Advanced robotics and AI infrastructure are poised to offset massive global labor shortages, presenting one of the most lucrative long-term investment vectors of the next decade.The real estate market is currently navigating the hyper-supply and recession phases of its cycle, making this the ideal time for patient capital to acquire distressed assets before rate cuts occur.Achieving a liquid, risk-free baseline of $5 million in Treasury bills provides a mathematical guarantee of financial freedom, effectively covering lifestyle costs through pure interest yield.CONNECT & TAKE ACTIONWealth Intelligence Brief: Text "WIB" to 844-447-1555 to get Matty's free macro data, real estate intel, and crypto signals delivered to your inbox 3 times a week.Imagos Income Fund: Text "INCOME" or "DEALS" to 844-447-1555 to learn more about Matty A's private debt fund targeting 10% fixed returns paid out monthly.

The L.A. City Council once gain moves to phase out oil drilling. Culver City teens could soon gain the right to vote. And what to know if you're camping at a national park this summer. Support The L.A. Report by donating at LAist.com/join and by visiting https://laist.comSupport the show: https://laist.com

This show has been flagged as Clean by the host. -------------------- 01 Introduction This is the second follow up to my 8 part series on nuclear power. In this episode I will attempt to answer a question posed by brian in ohio in a comment on HPR4583. In that comment he said: 02 -------------------- Loving this series. Maybe Whiskey Jack could give some cost comparisons between large and small reactors. He could also give us a realistic look at nuclear plant safety/accidents compared to conventional power production. Looking forward to the episode on FORTH generation reactors ;-) -------------------- 03 End of quote. The first question I answered in my previous follow up, which was HPR4628. In this episode I will attempt to answer the second question, which was about the safety of nuclear power compared to other sources of electrical power generation. One of the HPR janitors encouraged me to make this episode, so I think we can thank him for getting another HPR episode made. 04 Defining the Scope First, let's define the scope of the question. This will cover electrical power generation only. Within that scope I will consider only the following sources of energy. 05 Coal Oil Natural Gas Hydroelectric Nuclear Wind Solar I won't cover geothermal, wave, or tidal power as these are only used in very small amounts and so there simply isn't enough literature on them to base a discussion on . 06 Foreshadow Conclusion I should mention right away that I cannot provide absolute answers to this question in the form of a nice, neat ranking table based on numbers from peer reviewed scientific sources. The reasons for this will become apparent, but to put it briefly, the data on which to base such a ranking simply doesn't exist. I will however provide context within which people can think about the issue. Wherever possible, I will provide links to the references that I used in the show notes so you can read further on this yourself. -------------------- 07 Energy Catastrophism versus Energy Uniformitarianism First though I need to go off on a slight geological detour in order to explain an important analogy that I will use. 08 In the 19th century there was a great debate among geologists over what is known as catastrophism versus uniformitarianism. In seeking to explain the origins of the earth and of the landscape that we see around us, there were two points of view. 09 One was "catastrophism". This is the belief that the mountains, valleys, and plains that we see around us were formed as a result of great catastrophes which occurred relatively recently in earth's history. This explanation was necessary in order to fit geological features into an earth that was believed to be only a few thousands of years old. This view was heavily influenced by religious belief. In this view Noah's flood was the great catastrophe and the fossils of dinosaurs were the remains of animals who had not been saved on the ark and so had died in the flood. 10 The other point of view was uniformitarianism. This was the hypothesis that the landscape we see around us can be explained by the very slow accumulation of very small changes over very long periods of time. For this to be true however, the earth had to be far older than the few thousand years that a literal reading of the bible would suggest. The earth in fact had to be many, many, millions of years old. 11 Eventually, the uniformitarian view won out and people understood that while some catastrophes can take place, the shape of the landscape is overwhelmingly due to small changes over very long periods of time. 12 How is this Relevant to this Episode You Ask? How this is relevant is that I will use this analogy to explain how we need to think about energy and safety. Very small numbers of deaths and injuries multiplied over many occurrences can add up to big numbers, comparable in scale or possibly even larger than a single catastrophe or even several of them. 13 I don't know if anyone else has used this analogy before, I have just thought of this when writing the script for this podcast. None the less, I think it is a very useful way of helping to understand the issues. 14 As an example of this, think about the well known case of the safety of flying versus the safety of travelling in your car. Air crashes are catastrophes that make the headlines. Automobile crashes are seldom more than local news at best. You have probably heard many times the claim that if you making a trip somewhere, you are safer to fly than to drive yourself in your car. 15 Example - Hydro versus Solar I will now present an example of this. Hydro electric power has some notable large scale catastrophes associated with it. Roof top solar power does not have any notable catastrophes that I am aware of. However, which is safer? 16 Hydro Catastrophes Here are three examples of hydro electric catastrophes in just one country, Italy. The Vajont Dam which collapsed in1963 An estimated 1,917 to 2,500 people died. The Sella Zerbino dam which collapsed in 1935. More than 100 people died. The Gleno Dam which collapsed in 1923. An estimated 350 people died. https://damfailures.org/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4997708/ 17 I haven't tried to compile a global list of the worst hydro electric dam collapses, as this sort of information is actually very difficult to find, even on web sites dedicated to dam failures. An additional problem is that information on whether a dam was used for electric power generation or not is often not available. 18 Dam failures where contradictory or insufficient information is available on whether there was an associated hydro power plant include the 1975 Banqian Dam failure, where death estimates range up to a quarter of a million. 19 Solar Panel Slow Accumulation Contrast this with roof top solar panels. Many small accidents can add up to big numbers as well. 20 Health and safety literature discussing solar panel safety mention things such as Falls from roofs. Electric shock. Arc flash (burns from electrical arcing). Normal electrical safety procedures which are based around locking out sources of energy do not work with solar panels which makes safety more difficult. Heat stress due to working exposed in the hot sun. Warning from US government on falls by solar panel installers. https://stacks.cdc.gov/view/cdc/228946 https://www.osha.gov/green-jobs/solar 21 Why We Cannot Compare the Two Hydro catastrophes are not well documented, but we can at least find records of some of the most notable ones. However, even those have very large variations in estimates of deaths. 22 Roof top solar deaths however are largely undocumented. The industry is largely unregulated. There is no central authority which accumulates many individual deaths or injuries. At best there are worker and public safety bodies who simply accumulate those statistics into general construction or household injuries. 23 Thus we have no reliable means of comparing the two energy sources on a comparable basis. We face the same problem with all other major electrical energy sources. So far as I am aware, there are no peer reviewed scientific studies which compare the relative safety of all of the major electrical energy sources we are considering here based on actual numbers. -------------------- 24 Safety Risks I will now try to list some the major hazards for each of energy sources we are considering. There is however limited data available. In many cases we just have reference to worker safety organizations as to what the hazards are. I will not attempt here to put numbers to these here. Categories 25 Coal, Oil, Natural Gas The hazards are Air pollution Mining and oil field accidents Pipeline explosions Transportation accidents. These- move a lot of material so these are significant. 26 Hydroelectric These include Dam collapse Drowning 27 Nuclear These include Radiation exposure 28 Wind These include Falls Confined space deaths (there is not much detail on this) Electric shock Ice throws (that is, throwing pieces of ice off the blades) This technology has a significant problem with people working alone which greatly increases risks associated with other dangers. 29 Solar These include Falls Electric shock Arc flash Heat stress 30 I have not tried to cover all possible risks associated with each category, just the ones which each industry considers to be the risks they concern themselves with. There does not exist any means by which risks of similar types are compared across different industries. 31 Reliability of Supply is Also Safety In a completely electrified net zero society, reliability of supply is a safety matter. People will die in very large numbers in cold climates if they do not have heat. If we have no fossil fuels, we need to also consider how reliably does a grid based on any of the options work. I have not seen anyone attempt to address this question and will not attempt to address it here. However, it must be addressed in any comprehensive attempt to rank safety. -------------------- 32 Studies or Articles on Estimates of Relative Safety Despite the difficulties of comparing the safety of different sources of energy, some people have attempted this anyway. Different estimates done at different times had different focuses, so unfortunately we do not have a nice set of studies that we can neatly use to cross check one another. I will however list the names and the authors and summarize the results. -------------------- 33 The Health Hazards of Not Going Nuclear By Dr. Petr Beckman Published in 1976 The author of this book tried to address the relative safety of different sources of energy in the mid 1970s. However, it is old at this point, so I won't bother digging through its pages to find his figures. 34 He mainly focused on comparing electric power generated with coal to nuclear. His conclusion was that if the goal was to prevent deaths or ill health in the process of generating electricity, then the logical conclusion was to replace coal fired power plants with nuclear. 35 The book was relatively well known at the time, as least as far as books on energy are concerned, so I thought it was still worth mentioning. I happen to have a copy of this book which I bought back in that time period It was the 8th printing of the book, so it would appear to have had relatively good sales. 36 The author did address the issue of what I have termed "catastrophism" in his comparison of different energy sources, although I don't know if he used this phrase. I don't know if he was the first to use this sort of analysis, but he certainly was very influential in terms of popularizing it. -------------------- 37 Risk of Energy Production by Herbert Inhaber Publication AECB 1119 March 1978 This study is a scientific paper from the same time period as the book "The Health Hazards of Not Going Nuclear". 38 He based his risk estimates largely on estimates of the amount of material which was used in the construction and operation of various power sources. While we could argue over whether or not this is a valid methodology, I think any such argument would be pointless as I think the age of the study alone renders it not relevant today anyway. Advancements in materials have changed the basis results significantly by now. However, as it exists I thought I would mention it to show that the idea of comparing energy sources to each other is not a new one. The author compared a wider variety of potential sources than Beckman did. 39 Here's his conclusions. He assumes equal amounts of energy produced by each method. The numbers are normalized such that the total sums to 100%. You can think of it in terms of what proportion of total deaths or injuries would result from each source if each were equally used. 40 Coal 27.5% Oil 25.6% Methanol 16.7% Wind 10.8% Solar photovoltaic 9.2% Thermal 8.1% Solar space heating 1.5% Ocean thermal 0.4% Nuclear 0.13% Natural Gas 0.08% 41 His natural gas estimate is drastically different from that of other authors. I am not going to worry about explaining it however, as the study is as I said old enough to be not very relevant anyway. I am mainly including this here out of historical interest. 42 As a footnote, the methanol he refers to would be synthesized from wood. This was a popular idea in that era as a means of providing liquid fuels for transportation. Practical battery electric cars in those days were strictly science fiction. 43 The ocean thermal category is a real blast from the past and I had forgotten all about that concept. It was a very popular idea at that time and was supposed to be *the* big and upcoming thing in renewable energy. It involved various means of attempting to extract energy from differences in water temperature at different depths in the ocean. It gradually faded away however, as despite great efforts being put into it, designs never proved to be practical. -------------------- 44 Electricity generation and health Anil Markandya, Paul Wilkinson Published in the Lancet, Vol 370, 15 September 2007 45 This is more recent than the previous one, although it is nearly 20 years old at this point. Unfortunately it doesn't cover wind or solar, just fossil fuels and nuclear. However it is still useful, and the Lancet is a very reputable peer reviewed journal. 46 I will present just the results rather than discussing the whole paper. The authors break it down into deaths among the public, occupational deaths, and air pollution related deaths, serious illness, and minor illness. 47 They break the energy sources down into lignite, coal, gas, oil, biomass, and nuclear. Lignite is a type of very low grade coal used mainly for electric power generation. In this paper biomass refers to energy crops and forest residues. 48 I will summarize the results by category rather than trying to describe a table that has 6 rows and 5 columns. All numbers are normalized in terms of deaths or cases per TWh. 49 Occupational deaths from accidents lignite 0.1 coal 0.1 gas 0.001 oil no data biomass - no data Nuclear is 0.019. 50 Deaths among the public from accidents lignite 0.02 coal 0.02 gas 0.02 oil 0.03 biomass no data Nuclear 0.003 51 Air pollution deaths lignite 32.6 coal 24.5 gas 2.8 oil 18.4 biomass 4.63 Nuclear 0.052 52 Air pollution serious illnesses lignite 298 coal 225 gas 30 oil 161 biomass 43 Nuclear 0.22 53 Air pollution minor illnesses lignite 17,676 coal 13,288 gas 703 oil 9,551 biomass 2,276 Nuclear no data 54 Natural gas edges out nuclear power slightly in terms of occupational safety, but in every other category nuclear is drastically lower in terms of ill effects than any of the alternatives. -------------------- 55 2020 Fatalities for US Roofers Increased 15% as Solar Roof Installations Increase Published in The Next Big Future July 6, 2021 by Brian Wang 56 This seems to be written by someone who has a popular science blog. I'm not familiar with it personally, but he addresses the subject so I'll list it. The title implies that it's all about rooftop solar, but he provides comparative numbers for the other energy sources of interest, so that is useful for our purposes. However, he doesn't describe his methodology, so we need to treat them with some caution. Here are his results These are deaths per thousand terawatt hours. 57 Coal - 100,000 Oil - 36,000 Natural gas - 4,000 Hydro - 1,400 Rooftop solar - 440 Wind - 150 Nuclear - 90 58 If we plot these numbers on a bar chart, coal and oil are so large that all of the others are squished to the bottom of the chart and are difficult to see at all. Let's therefore look at these in terms of orders of magnitude. Keep in mind that this is a logarithmic scale. This means that the difference between 4 and 5 is much greater in linear terms than the difference between 1 and 2. 59 Coal - 5 Oil - 4 Natural gas - 3 Hydro - 3 Rooftop solar - 2 Wind - 2 Nuclear - 1 60 Each of these numbers represents an order of magnitude, that is a power of ten. We can see that with rooftop solar, wind, and nuclear, the numbers are so close and the uncertainties are so great and their relative values so small compared to say coal that they can be seen as equivalent so far as safety is concerned. -------------------- 61 What are the safest and cleanest sources of energy? by Hannah Ritchie Published in Our World in Data First published in 2017, updated in 2022 and 2024 62 The author of this study addressed both deaths and greenhouse gas emissions. Deaths from accidents and air pollution are normalized to per TWh of electricity, while greenhouse gas emissions are normalized to GWh of electricity over the life cycle of the plant. 63 Here are the death figures. Coal 24.6 Oil 18.4 Biomass 4.6 Natural Gas 2.8 Hydro power 1.3 Wind 0.04 Nuclear 0.03 Solar 0.02 64 For greenhouse gas emissions the figures are Coal 970 tons Oil 720 tons Natural gas 440 tons Biomass 78 to 230 tons Solar 53 tons Hydro power 24 tons Wind 11 tons Nuclear 6 tons 65 If we take the death figures and rank them by order of magnitude as we did with the previous article, we get the following. 66 Coal - 4 Oil - 4 Biomass - 3 Natural Gas - 3 Hydro power - 3 Wind - 1 Nuclear - 1 Solar - 1 67 Keep in mind that the previous article covered only rooftop solar and not large industrial installations, and so is not directly comparable. Also the units are different, with the previous article being in terms of thousand TWh, and this one being in TWh. If we exclude solar (as the numbers are not comparable), Brian Wang's numbers are between 1.5 to 4 times higher than Ritchie's, except for hydro which are almost identical. I think this latter is due to both sets of numbers are dominated by one exceptionally big hydro accident. 68 Overall however, the relative rankings are quite comparable. Ritchie's numbers for deaths from coal, oil, and natural gas appear to be directly from the study by Markandya and Wilkinson mentioned above. For the benefit of those who are wondering, Ritchie specifically states that her numbers for nuclear include the Chernobyl and Fukushima accidents. -------------------- https://www.iaea.org/publications/magazines/bulletin/21-1/solar-power-more-dangerous-nuclear Direct link to file https://www.iaea.org/sites/default/files/publications/magazines/bulletin/bull21-1/21104091117.pdf https://ourworldindata.org/safest-sources-of-energy https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)61253-7/abstract https://www.nextbigfuture.com/2021/07/2020-fatalities-for-us-roofers-increased-15-as-solar-roof-installations-increase.html -------------------- 69 Conclusion from Studies Remember that in engineering terms, when comparing groups of numbers which contain both both very small numbers and one or more very large numbers, the differences between the small numbers are often not significant. The differences between the small numbers may be the product of our ability to measure these things rather than any real differences. 70 For example, in the article by Ritchie wind power would appear to be twice as dangerous as nuclear. However, the difference between them is 0.02 compared to 24.6 for coal. In other words, the difference between apparently "dangerous" wind and apparently "safe" nuclear is equivalent to 0.08% of the total for coal. It's therefore meaningless and a red herring to even worry about. 71 With the above taken into consideration, generally the different sources of energy fall into two broad categories in terms of number of deaths, injuries, and illnesses. The fossil fuels and biomass fall into one group and wind, solar, and nuclear into another group. 72 Hydro power would seem to fall into the higher risk category or at least somewhere between the two, but this I suspect is mainly due to one exceptionally large dam collapse in China, the Banqian Dam failure in 1975. This is mentioned as being specifically included in the article written by Ritchie. This was a multi-purpose dam, and information on this dam is difficult to find. It is not clear to me whether it had a hydro electric generator associated with either it or another dam that was part of the same system. 73 Some people therefor may argue for its exclusion from the numbers. Of course some people may argue for its inclusion anyway, as it was a dam regardless of whether it actually had an electric generator attached. If we exclude it, then I think the numbers for hydro power would fall into the same range as for nuclear, wind, and solar. 74 Most people would consider hydro power to be safe and clean enough regardless of this and I will rank it as such in any conclusions that I come to. As you can see, even if we have numbers, it can be a matter of opinion as to how to interpret them. -------------------- -------------------- 75 Taking a Systems Approach Now let's take a look at the broader energy picture today and into the future. Many countries in many parts of the world have committed to the concept of "Net Zero", which means eliminating carbon emissions on a net basis. Net zero essentially means the complete electrification of society. We must therefore have electrical energy on demand and at low cost. We must as a result of this look at complete electrical systems rather than individual sources in isolation. 76 At one time many electrical systems were entirely coal or entirely hydroelectric. This is no longer the case. There are now major amounts of wind and solar involved in many countries. However these are inherently intermittent. This means that other sources of energy are inherently also required to have a functional system. 77 If any particular solution inherently requires fossil fuels to meet part of the demand, then the safety, pollution, and climate issues relating to those fossil fuels have to be factored in to that complete system when trying to come up with a relative ranking. Talking about Individual sources in isolation are therefore meaningless in these countries. 78 There are battery systems, but these are mainly used to stabilize and regulate the grid plus to a lesser degree to smooth out short term daily peaks in demand. They do not have the ability to store large amounts of electricity on a large scale for an entire grid for days, weeks, and months to make up for intermittency. 79 So a serious attempt to rank sources of energy would need to look at a variety of representative countries and for each one come up with a plan that involves 'x' megawatts from source 'a', 'y' megawatts from source 'b', etc., and total up the values for each. 80 I am not aware of anyone who has studied this larger issue. However, the problem has to be addressed from this perspective in order for any answer to be useful. Not taking this into account is like ordering a diet soft drink to go with with a high calorie meal and assuring yourself that your plans to diet are fine. 81 This is not to imply there is anything inherently wrong with wind or solar. It does mean that if your goal is to achieve both net zero and a clean environment, you have to look at your entire energy system as a complete system rather than focusing on what you feel are the most reassuring parts of it while ignoring the rest. This does however add to the argument that it is in fact inherently very difficult to come up with a system of ranking energy sources for safety. -------------------- 82 Nuclear, Climate, and Clean Air - Contrasting Examples To give a tangible example we will now look at two different places that followed two divergent paths at roughly around the same time frame. These are the province of Ontario in Canada, and Germany. 83 Ontario had a mix of coal, hydro electric, and nuclear generating plants. Germany had a mix of coal, nuclear and natural gas plants. Ontario shut down their coal fired plants and kept their nuclear plants. Germany however shut down their nuclear plants and kept their coal fired plants. 84 The Phase Out of Coal in Ontario In 2003 Ontario decided to close all of its coal fired generating plants, which consisted of 19 units (that is boilers and turbines) totalling 8,800 MW. This phase out was completed by 2014. 85 Here are the figures for amount of power generated by each energy source in 2003 and 2014. Nuclear went from 42% to 60% Hydro went from 23% to 24% Gas went from 11% to 9% Coal went from 25% to 0% Non-hydro renewable went from 0% to 7%. 86 As you can see, the bulk of that replacement came from increased use of nuclear power. Furthermore, this did not result in simply replacing coal with natural gas. While gas is cleaner than coal, it still has emissions and if you recall from the studies that we looked at earlier, had an estimated death rate roughly 2 orders of magnitude greater than nuclear, solar, or wind. 87 To put this in more practical terms, at one time Toronto regularly had clouds of smog obscuring it, to a large extent due to these coal fired power plants With the phase out of coal, smog days went to zero in 2015 compared to 53 a decade earlier. The 2023 figures for Ontario show carbon emissions of 53 grams per kWh of electricity generated. We can use this as a rough benchmark comparison for total emissions. 88 The Phase out of Nuclear in Germany Until March of 2011, Germany generated one quarter of its electrical power from nuclear. Starting in 2011 however, they began shutting down their nuclear power plants. These were then phased out over the next decade. However, the coal plants were to be kept to 2038. In 2026 Germany began talking about increasing use of coal in order to save gas. In the same year the German chancellor Friedrich Merz stated that the phase out of nuclear was a quote “serious strategic mistake”. EU Commission President Ursula von der Leyen said it was "a strategic mistake for Europe to turn its back on a reliable, affordable source of low-emissions power". 89 I won't go into the details of the phase out, but let's look at some emissions numbers for Germany. If we look at the official numbers from the European Environmental Agency for 2024, for Germany their emissions were 298 grams per kWh of electricity generated. Recall that we are using emissions as a very rough guide to amount of air pollution, and that this has a direct effect on the safety of the overall electrical energy system. 90 So, who actually made their people safer, Ontario who phased out their coal plants and kept their nuclear plants, or Germany who phased out their nuclear plants and kept their coal plants? 91 If you want a comparison directly within Europe, then Germany has one of the highest rates of emissions per kWh of electricity generated, whereas France, who use mainly nuclear power, have one of the lowest at 43 grams per kWh of electricity generated. Again, who is making their people safer, Germany or France? 92 I don't want to make it sound like I am picking on Germany. I am also not going to tell them how they ought to run their country. However they provide a good real world example of how we need to look at things in overall context when we are thinking about the choices that we make. https://www.ontario.ca/page/end-coal https://www.cbc.ca/news/canada/windsor/smog-study-shows-significant-decreases-in-pollutants-in-ontario-1.4151183 https://www.eea.europa.eu/en/analysis/indicators/greenhouse-gas-emission-intensity-of-1 https://world-nuclear.org/information-library/country-profiles/countries-g-n/germany https://www.politico.eu/article/friedrich-merz-is-right-to-reject-germanys-nuclear-phase-out-says-iea-chief-fatih-birol/ https://www.politico.eu/article/germany-considers-ramping-up-coal-power-to-avert-energy-crisis/ https://www.iea.org/countries/estonia/electricity https://www.iea.org/countries/malta/electricity -------------------- 93 Conclusions As we can see, there don't appear to be an abundance of peer reviewed scientific studies that we can simply point to in order to answer the question of safety of all possible major different energy sources once and for all. Collecting the data to even attempt to answer the question is inherently very difficult as we cannot readily conduct experiments to answer the question, and sources of data are not collected or consolidated in a manner which can answer this question adequately. 94 The essence of the problem is that most energy industries are not as tightly regulated and monitored to the same degree that say nuclear power or commercial airliners are, so this data is simply not being systematically recorded. However, a number of people have attempted to make estimates. 95 Their conclusions would seem to be that nuclear, wind, and solar are roughly equivalent in terms of safety. All fossil fuels are much less safe than nuclear, wind, and solar, by as much as several orders of magnitude. 96 We can however say with a reasonable degree of certainty that if a country shut down their nuclear power plants and kept their fossil fuel plants, particularly coal, then they probably made their people less safe than if they had done things the other way around. 97 I hope that I have provided some context in which to think about the issue. Thanks again to brian in ohio for providing the question upon which this episode is based. -------------------- Provide feedback on this episode.

This is no endless war! So what's the problem with this Iran deal? Maybe it's just that people don't know much about it. Fred Fleitz is Vice Chair of the America First Policy Institute Center for American Security, and he's got the details.

Vielleicht wird der Ruhestand doch nicht ganz so armselig, wie viele sagen. Vielleicht tritt der britische Premier Keir Starmer heute zurück. Und vielleicht war der neue Linkenchef Luigi Pantisano keine gute Wahl. Das ist die Lage am Montagmorgen. Hier die Artikel zum Nachlesen: Das ganze Interview hier: »Jeder bekommt aus der gesetzlichen Rente mehr raus, als er eingezahlt hat« Mehr Hintergründe hier: Keir Starmer ist schwer angeschlagen. Und jetzt beginnt die gefährlichste Phase seiner Amtszeit Mehr Hintergründe hier: Was die AfD-Aussage des neuen Linkenchefs über den Zustand seiner Partei verrät +++ Alle Infos zu unseren Werbepartnern finden Sie hier. Die SPIEGEL-Gruppe ist nicht für den Inhalt dieser Seite verantwortlich. +++ Mehr Hintergründe zum Thema erhalten Sie mit SPIEGEL+. Entdecken Sie die digitale Welt des SPIEGEL, unter spiegel.de/abonnieren finden Sie das passende Angebot. Alle SPIEGEL Podcasts finden Sie hier. Den SPIEGEL-WhatsApp-Kanal finden Sie hier. Hier geht es zu unserem SPIEGEL Shop. Alle Newsletter vom SPIEGEL finden Sie hier. Hier geht es zur SPIEGEL Akademie. Sie möchten den SPIEGEL mitgestalten? Registrieren Sie sich bei SPIEGEL Perspektiven. Informationen zu unserer Datenschutzerklärung.

Die Schweiz steht nach zwei Spielen an der Fussball-WM 2026 so gut wie sicher in der K.o.-Phase. Zeit für eine erste Zwischenbilanz: Welche Teams haben bisher überzeugt? Wer hat überrascht? Und welche Geschichten prägen dieses Turnier abseits des Nationalteams? Natürlich richtet sich der Blick aber auch auf das Team von Murat Yakin: Stellt der Trainer zu vorsichtig auf – trotz des Erfolgs gegen Bosnien-Herzegowina? Muss Johan Manzambi nach seinen starken Leistungen in die Startelf? Und weshalb steht Granit Xhaka bei jedem Turnier im Mittelpunkt? Ausserdem diskutieren wir die grösste Frage aus Schweizer Sicht: Wie weit kann es für das Team an dieser WM gehen? Die 351. Ausgabe der «Dritten Halbzeit» liefert Analysen, Debatten und Einschätzungen zwischen San Diego und dem Podcast-Studio in Zürich – inklusive eines Blicks auf ein überraschend abwesendes Thema: Wo steckt eigentlich US-Präsident Donald Trump an dieser WM? Die Themen: 00:00 Intro 01:46 WM-Stimmung in der Schweiz 08:13 Kein Trump, kein ICE, aber volle Stadien 17:57 Diese Teams haben überzeugt 27:26 Unser Eindruck der Schweiz 32:16 Dauerthema Granit Xhaka 40:39 Stellt Yakin zu ängstlich auf? 44:43 Ist Manzambi zu gut für die Bank 52:13 Vorschau auf das Kanada-Spiel 01:00:35 Ist Kobel gut genug? 01:05:07 Werbepausen, Experten und WM-Momente In der Dritten Halbzeit wird über den Schweizer Fussball diskutiert. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most exciting stories shaping the industry right now. Let's start with a groundbreaking advancement in gene therapy. Researchers have achieved a significant milestone by successfully using CRISPR technology to treat a rare genetic disorder in humans. This marks one of the first times that CRISPR has been applied directly to patients in such a way, offering hope for those suffering from conditions previously thought untreatable. This development is not just about treating one disorder; it opens up a world of possibilities for addressing various genetic diseases. By precisely editing genes at their source, scientists are paving the way for therapies that could revolutionize how we approach genetic disorders. Shifting gears to regulatory news, the FDA has granted accelerated approval to a new Alzheimer's drug that targets amyloid plaques in the brain. This drug, through its unique mechanism of action, aims to slow down cognitive decline in patients diagnosed with early-stage Alzheimer's disease. While there remains debate about the amyloid hypothesis itself, this approval signals a hopeful step forward in treating a condition that affects millions worldwide. As researchers continue to explore and understand Alzheimer's pathology, such approvals encourage further innovation and investment into neurodegenerative research. In clinical trial news, a biotech company has announced promising results from its Phase 3 trial of an mRNA-based vaccine for respiratory syncytial virus (RSV). The trial demonstrated high efficacy in preventing severe RSV infections among older adults, a population particularly vulnerable to this virus. These results not only underscore the versatility of mRNA technology but also highlight how quickly platforms developed during the COVID-19 pandemic can be adapted for other infectious diseases. This advancement suggests a future where rapid response to emerging viral threats becomes more feasible. Meanwhile, in the realm of oncology, there's been an exciting development with a novel immunotherapy showing potential in treating pancreatic cancer. This approach involves modifying patients' own immune cells to better recognize and attack cancer cells, a technique known as CAR-T cell therapy. Although traditionally successful in blood cancers, applying it to solid tumors like pancreatic cancer has been challenging due to their dense and protective tumor microenvironments. Early data indicate that this immunotherapy may penetrate these barriers more effectively, offering new hope for patients facing one of the deadliest forms of cancer. On a broader scale, the industry continues to see an increase in collaborative efforts between pharmaceutical giants and smaller biotech firms. These partnerships are essential for fostering innovation and speeding up drug development processes. By combining resources and expertise, companies can tackle complex health challenges more efficiently than ever before. Such collaborations also reflect an industry trend towards open innovation models that prioritize agility and shared knowledge over traditional competition. Finally, let's touch on an emerging trend that's capturing attention: personalized medicine's growing influence on drug development strategies. With advances in genomics and data analytics, pharmaceutical companies are increasingly tailoring therapies to individual patient profiles rather than adopting a one-size-fits-all approach. This shift not only improves treatment efficacy but also reduces the likelihood of adverse reactions, ultimately leading to better patient outcomes and more efficient healthcare systems. These stories illustrate an industry at the cutting edge of science and technology, driven by a relentless pursuit of new ways to improve human health. Each breakthrough not only represents progress but also carries profound implications for future research directions and therapeutic possibilities. That's all for today's edition of Pharma Daily. Stay tuned as we continue to bring you more updates on these exciting developments in pharmaceuticals and biotechnology. Thank you for listening, and we'll be back soon with more insights from this dynamic field.Support the show

Vor zehn Jahren spielte er noch in der Regionalliga, jetzt ist er Top-Performer bei der Weltmeisterschaft: In der fünften Folge des Ka Depp WM-Studios sprechen wir über Deniz Undav und den Einzug von Schland in die K.o.-Phase, über bemerkenswerte Schiedsrichterleistungen bei diesem Turnier und Maskottchen mit und ohne Hose. Im wie immer von der Sparkasse Nürnberg präsentierten Folge erklärt Experte Florian Zenger außerdem, warum die Türkei dominant spielte und trotzdem bereits nach zwei Spielen keine Zukunft mehr bei dieser WM hatte. Sportredakteur Wolfgang Laaß wiederum hat die DFB-Elf in den vergangenen Jahren oft aus der Nähe erlebt und spricht darüber, ob Bundestrainer Julian Nagelsmann eine Ära prägen könnte. Und dann ist da noch Prof. Dr. med. Kneginja Richter. Die Psychologin und Schlafforscherin von der CuraMed Tagesklinik Nürnberg und der Technischen Hochschule Nürnberg erklärt im Interview mit Sebastian Gloser, ob man für die Höhepunkte der WM vorschlafen kann, welche Folgen Schlafmangel schon nach kurzer Zeit hat und was man bei einem Powernap im Büro beachten sollte. Einen Gerch zum Miträtseln und einen Ausblick auf das letzte Vorrundenspiel der deutschen Mannschaft gibt es natürlich auch.

In this milestone episode (400), Andrea Samadi celebrates seven years of the Neuroscience Meets SEL Podcast with her husband Majid Samadi. They reflect on the journey of translating neuroscience into practical strategies for performance, learning, and well-being. Together they review core lessons — everything begins with the brain, safety before performance, how thoughts shape biology, the power of movement, recovery as a performance strategy, and the central role of relationships and support. Majid also shares leadership insights from his decades in educational sales, including stress management, motivation, continuous learning, and the guiding motto: do the right thing. They close by looking ahead to the next phase on movement, learning and cognition and invite listeners to subscribe for future episodes. Sales Leadership Under Pressure: Applying the Neuroscience of High Performance to Real-World Leadership Guest: Majid Samadi Listen to YouTube interview here https://youtu.be/SSZH3qwPqf8 Intro: Top 7 Lessons from the past 7 years Guest: Majid Samadi (Interview begins at 10:16) EP 400: Sales Leadership Under Pressure with Majid Samadi In this milestone 400th episode, Andrea welcomes back her husband, Majid Samadi, who first appeared on Episode 1 when the podcast launched in 2019. Together, they reflect on seven years, fifteen seasons, and 400 episodes of exploring the neuroscience behind achievement, leadership, learning, motivation, and human potential. In this episode, we will cover: ✔ The Top 7 Lessons Learned from 7 Years and 400 Episodes ✔ Why understanding the brain changes the way we learn, lead, and perform ✔ The neuroscience of stress, self-regulation, and leadership under pressure ✔ How high-performing leaders sustain motivation without burning out ✔ The connection between movement, learning, cognition, and peak performance ✔ Why relationships are the foundation of leadership and long-term success ✔ The role trust plays in building high-performing teams ✔ Leadership lessons learned through organizational change, uncertainty, and growth ✔ How the definition of success evolves over a lifetime and career ✔ Why no meaningful achievement happens alone As Andrea reflects on the lessons learned from hundreds of conversations with neuroscientists, educators, physicians, psychologists, business leaders, and peak performers, she shares the one lesson that stands above all the rest: Behind every meaningful accomplishment is someone who believed in you enough to help you keep going. Welcome back to Season 15 of the Neuroscience Meets Social and Emotional Learning Podcast. I'm Andrea Samadi, and on this podcast, we bridge the science behind social and emotional learning, emotional intelligence, and practical neuroscience so we can create measurable improvements in well-being, achievement, productivity, and results. Over the past 399 episodes, we've explored the neuroscience behind performance, learning, stress, motivation, and human potential. For this milestone Episode 400, I wanted to do something different. Instead of interviewing another neuroscientist, or reviewing past episodes, we're going to explore what happens when these ideas are applied in the real world. Joining me is someone listeners heard on EP 1[i] my husband, Majid Samadi, where we laid out the framework for future episodes, EP 200[ii] (Why we launched this podcast), and EP 300[iii] (a special episode with my Mom, Hazel MacPhail, where she taught us “how to live the good life”). I'll never forget EP 1, when I asked Majid if he would record with me to help me to launch this podcast thing I wanted to start. He had just come home from working LAUSD (in California) and he put his suit jacket on my desk, and sat down in front of the microphone. I showed him the questions I would ask him, and off we went. I learned that when you start something, it doesn't have to be perfect. Just start. What 15 Seasons Taught Me Before we begin today's conversation, I wanted to take a moment to reflect on what I've learned over the past seven years and 400 episodes of the Neuroscience Meets Social and Emotional Learning Podcast. I had sketched out a framework, and had some ideas of what I wanted to cover on at least the first 50 episodes. When I started this idea in 2019, I thought I was creating a platform to share neuroscience research (as it connected to Social and Emotional Learning). What I didn't realize was that the journey would change me. After hundreds of interviews with neuroscientists, physicians, educators, psychologists, business leaders, and peak performers, there are a few lessons that stand above all the rest. I'll always say it took me 50 episodes to get started. I found it really difficult to ask questions and breathe at the same time. Lesson #1: Everything begins with the brain. Whether we're talking about achievement, learning, leadership, health, relationships, or performance, success starts with understanding how the brain works. When we understand the brain, we stop fighting ourselves and start working with ourselves. We all have our own journey here. Mine started when an educator, Jeff Kleck, from EP 246[iv] challenged me to add neuroscience to my work. This was around 2014 when I had partnered with AZ Department of Education with a character ed/leadership program, and Jeff Kleck told me that I wouldn't go wrong if I wrote a whole new book that focused on the brain and learning. That's when I sat down, and started to study some of the leading researchers in this field. I've heard similar stories from other authors like Dr. Doug Fisher, who told me that he sat in classes with medical students to unwrap how the brain learns best. Lesson #2: Safety comes before performance. One of the most important themes of Season 15 has been that a dysregulated nervous system cannot perform at its best. Before growth, before learning, before leadership, the brain must feel safe. This lesson applies in our homes, our schools, our workplaces, and our relationships. I'll never forget asking Dr. David Stephen on EP 388[v] about a situation where I was under unusual stress, and my eyesight (or ability to read) stopped working. He explained the neuroscience behind this example, that I'll never forget and his solution to my problem that was to eat glucose before any important meeting or presentation. Lesson #3: Our thoughts become biology. Through experts like Dr. Caroline Leaf, Bob Proctor, Dawson Church, and many others, I learned that our thoughts are not just ideas. They influence our chemistry, our attention, our habits, and ultimately our results. What we repeatedly think becomes what we repeatedly do. This one I've believed since my days working in the seminar industry with Bob Proctor. He would hammer this concept into everyone's mind in every seminar. I just always thought this was something he really believed in, until I heard the SAME thing from Dr. Caroline Leaf, and Dr. Korotkov from Russia. It's also behind Dr. Joe Dispenza's work. To this day, I watch the words I think and say out loud. Lesson #4: Movement changes the brain. This lesson became personal. The science is clear: movement improves attention, memory, mood, resilience, and learning. But over the years, I experienced it firsthand through hiking, walking, strength training, and building daily movement into my life. This is how I've always been. I remember putting on my rollerblades when I was 16 and rollerblading to the local YMCA that wasn't really in my neighborhood. Motivation got me moving. Movement changed my brain. And this is how I still find the energy to sit at my desk and write podcasts episodes every Saturday. I have to exercise (or move) first, and then I can create. Over time this has probably been my healthiest habits. Lesson #5: Recovery drives performance. For years I focused on doing more. The neuroscience taught me something different. Growth doesn't happen during effort. Growth happens during recovery. Sleep, stress regulation, recovery, and reflection are not luxuries—they are performance strategies. This took me years to finally put into practice. Lesson #6: Relationships change everything. If there is one lesson that appears in every field of neuroscience, it is this: We are wired for connection. The quality of our relationships influences our health, happiness, resilience, leadership, and longevity. And that brings me to perhaps the most important lesson of all. Lesson #7: No meaningful achievement happens alone. People often see the finished podcast episode. They don't see the support system behind it. For 400 episodes, there has been one person supporting this mission from behind the scenes. My husband, Majid. While I was researching, writing, recording, editing, and building this platform, Majid was encouraging me when things were difficult, celebrating the wins, offering perspective when I needed it, and helping me continue when the path wasn't always clear. Many of these episodes were written because someone believed in me enough to keep me going. The podcast may have my name on it, but it has always been supported by both of us. As we celebrate Episode 400, that's the lesson I want to leave everyone with. Achievement is rarely a solo journey. Behind every meaningful accomplishment is a person, a mentor, a teacher, a spouse, a friend cheering you along the way from the sidelines, or a community that helped make it possible. The neuroscience taught me how the brain works. Life taught me that relationships are what make everything work. And that's why there is no better person to join me for Episode 400 than Majid Samadi. Welcome Majid! Thank you for taking the time to record this milestone episode with me. I know your time is limited. Before we get started, can  you share what it is that you do when you are not being strong armed to record podcast episodes for me? So, we have been covering 5 phases in Season 15, showing how the brain comes online and changes with each phase. So I've got some questions for you that will cover each phase. Does that sound good?

The Four Phases of Making Money Online With ChatGPT (And Exactly Which One You Should Be In Right Now) | Entrepreneur AI Guide Episode Summary Make money online as an AI entrepreneur by understanding ChatGPT's four income phases. Tracy breaks down the evolution from 2022's prompt-selling craze through 2025's audience-driven, systems-based models—and reveals exactly which phase matches your skill level and timeline. If you've wondered whether it's too late to build AI side income, this episode shows you're probably using outdated tactics. The future isn't about tools; it's about positioning. https://DarkHorseEntrepreneur.com Tracy breaks down the full evolution of making money with ChatGPT — from the wild west prompt-selling days of 2022 all the way through to the audience-driven, systems-based income models dominating 2025 and beyond. Ace walks through four distinct phases of the ChatGPT economy, explains why most people are playing the wrong phase right now, and reveals the one mindset shift that separates parents who build real AI-powered income from those who keep chasing the next shiny tool. If you've ever wondered whether it's too late to make money with AI, this episode gives you the honest, no-fluff answer. AI Micro Business Newsletter - https://DarkHorseInsider.com     In This Episode You'll Discover Why the ChatGPT prompt-selling gold rush collapsed by March 2023 — and what actually replaced it The four distinct phases of the ChatGPT economy and exactly which one has the real money right now Why the skill you're selling was never ChatGPT — and what you're actually selling instead The concept of information asymmetry and why your niche expertise is worth more than any AI tool on the market Why owning your audience is the only moat that survives every AI model update The invisible threshold between trading time for money and building a system that runs without you Why being a business person who uses AI beats being an AI person trying to do business — every single time     Key Timestamps 00:00 - Opening: The AI side hustle window is closing 01:10 - The before-ChatGPT era and what changed in November 2022 01:50 - Phase 1: The prompt engineers and the first wave of money-makers 02:50 - Phase 2: The shift from knowledge to implementation 04:30 - Phase 3: Selling systems instead of labor 05:05 - Phase 3.5: The GPT Store opportunity 07:45 - Phase 4: What's coming and why it changes everything 08:40 - The uncomfortable truth about the easy money phase 09:50 - Information asymmetry — the real scaling mechanism 11:50 - The uncomfortable truth about timing 12:35 - Which phase should YOU be in right now? 15:20 - The oldest pattern in economic disruption 17:30 - Whiskered Wisdom: The shovel doesn't dig the mine     Key Quotes From This Episode "Those people weren't actually selling prompts. They were selling permission — the feeling that you could do something you weren't sure you could do." "The skill you're selling isn't knowing ChatGPT. It's knowing your market so well that you can make ChatGPT produce what your market is actually hungry for." "You need to be a businessperson first — a businessperson who just happens to use AI. Not an AI person trying to be a businessperson." "The actual scaling mechanism in an AI-powered business isn't the AI. It's information asymmetry." "The AI is invisible. The business is visible." "The real game is always the same game: build trust, deliver results, and repeat. The AI just makes those first two steps way faster." "The shovel does not dig the mine. The miner does."     The Four Phases of ChatGPT Income — Quick Reference Phase Model Status Phase 1 Sell Knowledge (Prompts, Courses) Closed Phase 2 Sell Labor (Implementation Services) Narrowing Phase 3 Sell Systems (Agencies, Automation) Open Phase 3.5 GPT Store (Custom GPT Subscriptions) Wide Open Phase 4 Own Your Audience (Email List, Community) The Gold Mine     Your Action Step — Do This Right After Listening Open ChatGPT and type this prompt: "I am an expert in [your area of expertise]. Help me identify three ways that I could use AI to deliver value to others in this space and generate income." Read what comes back. Pick one. Write it down. That's your front door to the gold mine.     Resources Mentioned AI Escape Plan Newsletter — Weekly practical AI-powered strategies for parent entrepreneurs DarkHorseInsider.com — Sign up for your free spot in the newsletter ChatGPT Plus — OpenAI's premium tier ($20/month) GPT Store — OpenAI's marketplace for Custom GPTs Zapier / Make.com / N8N — Automation tools for building AI-powered workflows     Connect With Ace Allan & The Dark Horse Entrepreneur Website: DarkHorseEntrepreneur.com Newsletter: AI Escape Plan — sign up at DarkHorseInsider.com Podcast: The Dark Horse Entrepreneur AI Escape Plan     If this episode fired you up, share it with a parent who's been on the fence about AI. They need to hear it as much as you do. Think Successfully and Take Action!  

Send us Fan MailShow notes On January 1, 2027, every global OB code your practice has billed for the last thirty years is being deleted. Seventeen CPT codes. Gone. Replaced with a completely new structure for how every dollar of maternity revenue is earned, attributed, and collected. And the real deadline for your practice is not January 1, 2027. The real deadline is right now. What is actually going away For over thirty years, OB practices have lived in a bundled global world: one patient, one pregnancy, one code. Effective January 1, 2027, 17 global obstetric CPT codes (including 59400 for a global vaginal delivery and 59510 for a global C-section) are being deleted entirely. The AMA and ACOG determined the global model no longer reflects modern OB standard of care, and so the structure is being fully replaced, not patched. The four new phases of maternity billing Phase 1, Antepartum care. All bundled antepartum codes deleted. Every prenatal visit billed as individual E/M with TH modifier (99202 through 99215). Phase 2, Labor management. New dedicated code category for the first time in CPT history. Reported per calendar day, with straightforward vs complex management distinction. Phase 3, Delivery. Vaginal vs cesarean restructured. VBAC coded differently than first-time vaginal. Add-on procedures (3rd/4th degree laceration repair, uterine tamponade) now separately billable. Phase 4, Postpartum care. All existing postpartum codes deleted. Hospital care codes for inpatient day-after-delivery. Office E/M for outpatient follow-up. Same-date postpartum bundled into delivery. Why the real deadline is Q3 and Q4 2026 Cash flow in January 2027 will be decided this Q3 and Q4. Payer contracts reference CPT codes by number, so contracts that reference deleted codes need renegotiation now. Documentation habits have to change before the new codes go live, because every prenatal visit now needs to support E/M level selection. A 200-patient OB practice undercoding prenatal visits by even $40 each is leaving close to $100,000 a year on the table from day one. The multi-provider attribution problem Under the global model, attribution was easy: one practice, one fee, regardless of which provider saw which visit. Under the new model, every encounter is attributed to the individual provider who performed it. Practices with midlevels, hospitalists, or shared call need a clear protocol for labor management billing, on-call coverage, and cross-coverage now, or they will either double-bill (compliance risk) or miss charges (phantom revenue) from day one. Three actions this week Pull a payer contract audit. List every commercial contract referencing global OB codes that needs renegotiation before January 1. Run a prenatal documentation review. Pull 10 recent prenatal charts per provider and assess them against current 99213 and 99214 E/M standards. The gap is your single biggest revenue risk. Map your provider attribution workflow. Write out exactly how labor management, on-call coverage, cross-coverage, and same-day postpartum care will be tracked when every encounter is attributed individually. Episode breakdown 1. The 17 deleted codes 2. The four new phases of maternity billing 3. Why Q3 and Q4 of this year is your real deadline 4. The multi-provider attribution gap 5. What patients will see on their EOBs 6. Your 90-day action plan 7. What is ahead in the rest of the OB Global Coding Series Resources → Live OB Global Updates Webinar (PRIMARY): eligibility.natrevmd.com/obgyn-global-updates-webinar → Book a call with Heather: calendly.com/heather-natrevmd → Payment Posting Audit Checklist: eligibility.natrevmd.com/payment-posting-checklist → Practice Revenue Leak Scorecard: eligibility.natrevmd.com/nrm-revenue-scorecard-v3 → Coming next in the series: EP189 — How to Bill Antepartum Care Under the New E/M Model 

Die Schweiz gewinnt ihr zweites Gruppenspiel gegen Bosnien-Herzegowina überzeugend 4:1 und steht damit praktisch in der K.o.-Phase der Fussball-WM 2026. Doch die Partie kippt erst nach der entscheidenden «Hydration Break» in der zweiten Halbzeit. Beim Stand von 0:0 beweist Murat Yakin ein goldenes Händchen: Mit Johan Manzambi und Ruben Vargas bringt er genau die Spieler, die das Spiel zugunsten der Schweiz entscheiden. Vor allem Johan Manzambi liefert eine beeindruckende Antwort auf die Kritik nach seinem Auftritt gegen Katar. Der 20-Jährige wird zum Matchwinner und prägt den Schweizer Sieg mit seinen zwei Toren und einer herausragenden Leistung. Aber auch Granit Xhaka zeigt einmal mehr, warum er dann besonders stark ist, wenn der Druck am grössten ist. In der 350. Ausgabe der «Dritten Halbzeit» – oder neu: «Fünftes Viertel» – analysieren Tilman Pauls und Dominic Wuillemin den Schweizer Sieg direkt aus dem Stadion in Los Angeles: die Startelf von Murat Yakin, die taktische Bedeutung der Trinkpause, die Schlüsselspieler der Partie und die Atmosphäre auf den Rängen. Eine Folge über starke Wechsel, mutige Entscheidungen und einen Abend, der für die Schweiz richtungsweisend sein könnte. Die Themen: 00:00 Intro 05:00 Die Kraft der Trinkpause 09:53 Parallelen zum Katar-Spiel 15:52 Shootingstar Johan Manzambi 22:39 Die Reaktion von Granit Xhaka 28:26 Stimmung und Stadion In der Dritten Halbzeit wird über den Schweizer Fussball diskutiert. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Nerds rank all the films of Phase 2 of the Marvel Cinematic Universe!

Mexiko wurde nach einem Sieg über die Republik Korea am 8. Spieltag das erste Team, das die K.o.-Phase der FIFA-Weltmeisterschaft 2026™ erreicht. Gleichzeitig schrieb Kanada Geschichte mit einem Rekordsieg von 6:0 gegen Katar. Die Schweiz festigte ihre Position mit einem 4:1-Erfolg gegen Bosnien und Herzegowina.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry continues to evolve, with significant scientific advancements, regulatory updates, and strategic business moves shaping the landscape. Let's delve into these developments, starting with some key insights from oncology. In the realm of oncology, minimal residual disease (MRD) is becoming increasingly pivotal. Tumor-informed MRD is being leveraged to design more intelligent trials and interpret early responses, aiding in navigating developmental risks more effectively. This approach was a focal point of discussions at the American Society of Clinical Oncology's annual meeting, where experts emphasized the need to translate precision oncology discoveries into patient care, aiming to surmount existing challenges. The focus on MRD in oncology could lead to earlier detection of treatment responses and personalized therapeutic approaches. Verastem Oncology recently revisited its strategy concerning its combination treatment of avutometinib plus defactinib for metastatic pancreatic cancer. While clinical trials produced moderate results, the company is now redirecting focus toward other promising candidates in its pipeline. Similarly, Novocure faced setbacks as its tumor-treating electric fields device did not achieve its primary endpoint in a Phase 3 glioblastoma trial. These outcomes highlight the persistent challenges in tackling aggressive brain cancers. On the regulatory front, Spero Therapeutics achieved a significant milestone with FDA approval for Utebzi to treat complicated urinary tract infections. This approval marks a turnaround from a previous rejection four years ago, facilitated through a partnership with GSK. Meanwhile, in Europe, Cinnagen secured approval for Zandoriah, a biosimilar of teriparatide, to treat osteoporosis in adults—a testament to their investment in infrastructure and manufacturing capabilities. The industry also sees growing interest in cell therapy automation, with companies like Cellares and Ori Biotech leading the charge. These advancements reflect an industry-wide push towards more efficient manufacturing processes for cell therapies. In metabolic health, Novo Nordisk's oral GLP-1 drug Wegovy has gained significant traction due to its brand familiarity among healthcare providers, crucial in its competition with Eli Lilly's Foundayo. Market trends reveal competitive dynamics within obesity treatments as Novo Nordisk's oral Wegovy outpaces Eli Lilly's offerings due to strong brand recognition. Biogen's acquisition of Raythera for $1 billion underscores its strategic intent to enhance its portfolio with promising preclinical immunology assets. Such acquisitions highlight broader industry strategies focusing on expanding pipelines through targeted investments. This move aligns with Biogen's focus on autoimmune diseases and enhances its preclinical portfolio. In business development news, LabGenius Therapeutics partnered with LG Chem to utilize AI and machine learning for designing multispecific antibodies targeting tumors. This collaboration highlights the growing importance of artificial intelligence in accelerating drug discovery processes within oncology. Clinical trials continue to yield promising results. F2G and Shionogi's antifungal small molecule olorofim demonstrated efficacy comparable to Ambisome in treating invasive aspergillosis—an advancement crucial for infectious diseases with limited treatment options. D&D Pharmatech's Zabopegdutide showed an impressive improvement rate in fibrosis during Phase 2 trials for metabolic dysfunction-associated steatohepatitis, emphasizing the potential of protein-based therapies in treating metabolic liver disorders. Corporate launches reflect strategic maneuvers aimed at advancing therapeutic developments. Innoviva introduced Nortiva Bio to focus on long-acting oral medicines using acquired platform technology from Lyndra Therapeutics—aiming to revolutionize women's health through sustained-release formulations. The financial landscape also shows active movement, exemplified by Kardigan's $400 million IPO aimed at progressing cardiovascular drugs into advanced trials. Alvotech's public offering signals a commitment to biosimilar medicines—a sector poised for growth due to rising demand for cost-effective biologic therapies. Overall, these developments reflect a robust innovation pipeline within the pharmaceutical and biotech industries as they strategically address complex diseases through novel therapies and technologies. As scientific progress accelerates alongside strategic corporate actions, these changes promise enhanced patient care outcomes through groundbreaking treatments that cater to unmet medical needs worldwide.Support the show

Gegen Katar hat sich die Schweiz noch die Zähne ausgebissen, gegen Bosnien Herzegowina leitet ein traumhafter Volley-Treffer von Johan Manzambi den ersten Sieg in Gruppe B ein – 4:1 am Ende.Aber auch der Co-Gastgeber Kanada darf jubeln, denn der eindeutige 6:0-Sieg gegen ein überfordertes Katar stößt die Tür zur K.o.-Phase weit auf. Allerdings wird die Freude der Kanadier durch die Verletzung von Ismaël Koné getrübt. Mexiko qualifiziert sich als erstes Team und Gruppenerster für die K.o.-Runde durch einen umkämpften 1:0-Sieg gegen Südkorea. Im anderen Spiel der Gruppe A steht zwischen Tschechien und Südafrika ein 1:1-Remis, das keinem so wirklich weiterhilft. Vor allem die Tschechen müssen sich nach einer verspielten Führung ärgern.Für das DFB-Team ist es Matchday-1 vor dem zweiten Gruppenspiel gegen die Elfenbeinküste und Alex Schlüter erzählt aus dem Quartier in Winston Salem, wie die Stimmung kurz vor dem Aufbruch zum Spielort Toronto ist.Und dann wird noch auf den kommenden WM-Tag geschaut, an dem die USA nach furiosem Start auf das Überraschungsteam aus Australien trifft. Die Türkei steht dagegen nach der Auftaktniederlage unter Druck und braucht einen Sieg gegen Paraguay.Und auch Gruppe C geht an den Start. Hier wollen Brasilien und Marokko nach dem Auftaktremis ihren ersten Sieg holen. Brasilien trifft auf Haiti, Marokko bekommt es mit Schottland zu tun.Wie immer begleiten wir euch täglich durch die Weltmeisterschaft – mit den wichtigsten Ergebnissen, spannenden Geschichten, Eindrücken aus den Stadien und allem, was ihr rund um das Turnier wissen müsst.Alles wichtige zur WM und der deutschen Nationalmannschaft gibts hier:Fußball-WM 2026: News, Videos und Spielplan zur WM 2026Alle Live- und Audiostreams zu den WM-Partien findet ihr hier: https://www.sportschau.de/fussball/fifa-wm-2026/alle-livestreams-zur-wm-2026,stream-uebersicht-100.…(00:00) Intro(00:50) Mexiko in der K.o.-Runde(02:00) Tschechien und Südafrika mit Remis(02:55) Kanada mit Schritt Richtung K.o.-Runde(04:30) Schweiz mit dem Brustlöser-Sieg(07:35) Blick auf das DFB-Team mit Alex Schlüter(15:50) Vorschau USA-Australien(17:40) Vorschau Türkei-Paraguay(19:05) Vorschau Schottland-Marokko(20:50) Vorschau Brasilien-Haiti

Was tun, wenn alles schiefgeht? Im Business aber auch im Leben oder in der Beziehung... Jeder spricht über Erfolg. Doch die wirklich wichtige Frage lautet: Was machst du, wenn dein Business nicht läuft? Wenn du Rückschläge kassierst? Wenn du an dir selbst zweifelst? Wenn das Leben plötzlich komplett anders läuft als geplant? In dieser Folge vom Next Level Business Podcast sprechen wir über die Fähigkeit, die erfolgreiche Menschen von allen anderen unterscheidet: Nicht Talent. Nicht Glück. Nicht Geld. Sondern Resilienz. Die Fähigkeit, auch dann weiterzumachen, wenn alles gegen dich läuft. Wir sprechen darüber: * wie erfolgreiche Unternehmer mit Krisen umgehen * warum Rückschläge zum Erfolg dazugehören * was du von Menschen wie Elon Musk lernen kannst * wie du mentale Stärke aufbaust * warum Emotionen oft schlechte Entscheidungen verursachen * und wie du selbst in schwierigen Zeiten die Kontrolle behältst Die meisten Menschen geben auf, wenn es schwer wird. Die erfolgreichsten Menschen werden genau in diesen Momenten geformt. Wenn du aktuell eine schwierige Phase durchmachst, privat oder im Business – dann ist diese Folge für dich. Denn manchmal ist der größte Durchbruch nur eine schwere Zeit entfernt.

Welcome back to RECESS — our bi-weekly look at what we're learning, trends we're seeing in the health and fitness space, and how we're building more play into real life.The fitness industry is facing its biggest shake-up yet, and it's coming from a syringe. In this episode of RECESS, we cover a lot of ground: from Caroline's high school graduation and a wild weekend of sports (Knicks championship! Water polo! World Cup!) to the questions keeping health and fitness professionals up at night.The centerpiece of this episode is a candid conversation about GLP-1, GLP-2, and the newly trialed GLP-3 drug Retatrutide — and what near-30% body weight loss results mean for the future of personal training, nutrition coaching, and the entire weight loss industry. Is weight loss about to become a purely medical intervention? And if so, what does that mean for coaches, trainers, and wellness brands like ours?We also take on a viral debate about AI-generated fitness influencers crowding out real coaches on social media, break down the data on whether women should skip college in the age of AI (spoiler: the numbers say no), and share our take on Backrooms, the buzzy horror film directed by a local kid who built the concept as a high schooler. If you've ever felt the existential dread of liminal spaces, this one's for you.What You'll Learn in This EpisodeWhy Caroline Starrett's observation that "muscles are the new skinny" might be the most important trend call in fitness right nowHow GLP-3 drug Retatrutide achieved nearly 30% average body weight loss in Phase 3 trials, and what that means compared to Ozempic and ZepBoundWhat happens to the fitness industry if weight loss becomes a purely pharmaceutical interventionThe hidden dangers of GLP-1 drugs: muscle and bone mass loss, weight regain after stopping, and the return of extreme thinness cultureWhy AI-generated fitness influencers are getting millions of views while real coaches struggle for reach, and what to do about itThe data behind college ROI for women: why the gender pay gap and VC funding stats make a compelling case for staying in schoolWhy the most successful female founders (Rent the Runway, Stitch Fix, 23andMe, Tory Burch) share one thing in commonA local director's Backrooms, worth seeing even if you hate horrorKey Highlights: (00:00) Welcome back to RECESS; Caroline's high school graduation and becoming (almost) empty nesters; the "open nest" philosophy(01:50) A massive weekend of sports: Knicks championship, Stanley Cup, World Cup, water polo tournaments, and shoutouts to Cal athletes competing in European club championships(05:35) The viral Canadian coach's Instagram post: AI-generated fitness influencers vs. real coaches, the algorithm problem, and a defense of making content that's actually fun(07:45) Why real coaches deserve your engagement: the difference between AI-driven content and educators who've spent years building free resources(11:17) College ROI debate: a prominent female entrepreneur suggests skipping college; Juliet and Kelly push back with data — 65–75% higher lifetime earnings for college grads, and the gender pay gap closes with education(16:00) Female founders and elite credentials: why the women who actually break through in VC-backed startups almost universally have top-tier degrees; notable examples and one cautionary tale(18:00) Caroline's insight: "muscles are the new skinny" — when anyone can change their body composition with a GLP drug, muscle becomes the differentiator(19:29) Breaking down the GLP-3 trial results for Retatrutide: 70+ lbs average loss, nearly 30% body weight reduction, and how it compares to GLP-1 and GLP-2 drugs(20:40) How GLP drugs are splitting the fitness industry: some coaches relieved, some threatened, and the legacy weight loss brands already pivoting(22:45) The dark side: muscle and bone mass loss, Hollywood's return to extreme thinness, and what happens when people stop taking the drugs without changing their habits(27:00) The message that still matters: muscle is your longevity organ; building a body for adventure; why GLP drugs and strength training aren't mutually exclusive(27:29) Backrooms the movie: local Marin School of the Arts alum director Kane Parsons, and why this creepy-beautiful film is worth your time even if you're not a horror fan(29:10) Wrap-up and thanks for listening

Heute geht's ans Eingemachte: Naschen, Quetschis und das schlechte Gewissen, das ihr alle kennt. Wisst ihr noch, wie ihr mal die mit der Gemüseschale werden wolltet? Tja. Bei uns gibt's Gummibärchen, Snackwaffeln und jeden Tag ein Eis – und dann gucken wir neidisch auf die Brotdosen mit Paprika und Apfel von den vernünftigen Hipster-Kindern. Wir reden drüber, warum die Kleinen abends auf einmal Hunger haben (Spoiler: ist meistens kein Hunger), ob man mit zwei Abend-Quetschis schon eine Essstörung triggert und warum klare Regeln am Ende für alle einfacher sind. Dann wird's wild: Alinas Baby robbt seit Neuestem wie eine Schildkröte aus dem Ei, hatte prompt einen Stein im Mund (Herzstillstand inklusive) und wir steigen offiziell in die wilde Phase ein. Dazu die Geschwisterliebe, mit der echt niemand gerechnet hat, ein Honig-Fun-Fact, der euch umhaut, und Alinas früheste Kindheitserinnerung, die… sagen wir mal: Addams-Family-Energie hat. Und weil das Leben gerade eh komplett auf Anschlag läuft, reden wir ehrlich über den Druck als Selbstständige mit zwei kleinen Kindern, Hausbau, Umzug und die Dauer-Angst, dass alles den Bach runtergeht. Alina, du machst gerade das heftigste Jahr deines Lebens durch – sei mal ein bisschen weich zu dir. Zum Schluss geht's noch auf Malle (erster Urlaub mit Baby!) und Fanny hat einen Airbnb-Tipp, der euch echt Geld sparen kann. Nächste Woche covern wir euren KI-Fomo: Die erste „KI für müde Mutties"-Folge kommt. Safe. MOMSPLAINING: Ihr habt eine Geschichte, einen Fall oder einfach was, das euch von der Seele muss? Schickt's an fanny@mamaleisa.de – wir lesen alles. Du bist schwanger und fühlst dich gerade überfordert, unsicher oder allein? Das Hilfetelefon „Schwangere in Not“ ist jederzeit für dich da – anonym, kostenlos und in 19 Sprachen. Du bist nicht allein: www.hilfetelefon-schwangere.de Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte: https://linktr.ee/mama_leisa Du möchtest Werbung in diesem Podcast schalten? Dann erfahre hier mehr über die Werbemöglichkeiten bei Seven.One Audio: https://www.seven.one/portfolio/sevenone-audio

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a rapidly evolving landscape marked by significant scientific breakthroughs, regulatory shifts, and strategic business maneuvers. The pharmaceutical and biotech sectors are buzzing with renewed vigor, as evidenced by an impressive resurgence in mergers and acquisitions. A recent analysis by PwC reports that M&A activity has reached over $65 billion in deal value during the first quarter of 2026, marking the strongest quarter since 2020. This uptick underscores a robust confidence within the industry, with companies strategically leveraging these mergers to bolster their pipelines and explore new therapeutic territories. Eli Lilly's acquisition of non-opioid pain drugmaker 4E is a case in point, as it reflects a broader industry shift towards precision medicine and non-opioid pain management solutions—a response to growing concerns over opioid addiction. On the regulatory front, notable developments include Colorado's drug import plan receiving FDA approval. This marks a bold step in curbing drug costs across the U.S., although implementation challenges remain due to complex logistical and regulatory landscapes. Meanwhile, Novo Nordisk is expanding its global manufacturing footprint with a new plant in the Czech Republic for diabetes and obesity drugs, alongside a $29 million investment to upgrade its Chinese facility. This expansion aligns with Novo's strategic preparation to seek Chinese regulatory approval for its Wegovy pill, potentially transforming the obesity treatment landscape. In a move that could reshape vaccine development, Moderna is advancing its mRNA-based influenza vaccine candidate through regulatory channels. The FDA's favorable reviews ahead of an advisory committee meeting highlight the growing acceptance of mRNA technology beyond COVID-19 vaccines. This technology holds promise for transforming vaccine development across various infectious diseases. Precision oncology continues to grapple with translating scientific discoveries into practical applications that genuinely improve patient outcomes. The ASCO 2026 conference emphasized this critical transition from discovery to implementation as essential for advancing precision medicine. Turning to gene therapy, UniQure is preparing for a significant milestone—submitting an accelerated Biologics License Application for its Huntington's disease therapy. This follows a reversal by the FDA, which now considers UniQure's Phase 1/2 trial data sufficient for submission. Should this therapy gain approval, it would be groundbreaking as the first genetic medicine for Huntington's disease, setting a precedent for future gene therapies targeting other genetic disorders. In another strategic partnership, Jazz Pharmaceuticals has teamed up with AbCellera to develop T-cell-engaging antibodies for oncology indications, illustrating the potential financial rewards associated with innovative cancer therapies. This collaboration could yield up to $820 million per program and highlights how partnerships are crucial in expediting drug development timelines. These stories reflect broader industry trends emphasizing innovation and strategic partnerships while navigating complex regulatory landscapes. The focus on precision medicine and advanced biologics continues to drive scientific advancements, with companies like Vedana Therapeutics targeting unmet needs in neurology through novel therapeutic approaches. Meanwhile, international collaboration is gaining traction in regulatory processes. The newly launched transatlantic liaison program between the FDA and MHRA aims to accelerate drug approvals and foster innovation across borders—an initiative that underscores the importance of collaborative frameworks. However, not all news is optimistic. Be Biopharma's decision to terminate its hemophilia B cell therapy trial highlights the challenges companies face in competitive therapeutic areas. Despite previous optimism, similar withdrawals by Pfizer and BioMarin indicate the necessity for robust clinical data and clear market differentiation strategies. Furthermore, Merck's recent agreement with Protillion Technologies marks an increased focus on integrating artificial intelligence into drug discovery processes—a trend promising accelerated timelines and improved trial success rates. As these developments unfold, it's evident that the pharmaceutical and biotech sectors are at an intersection where scientific innovation meets strategic business decisions. The potential approval of UniQure's gene therapy could catalyze further advancements in genetic medicine—while M&A activities suggest an industry poised for transformative growth. For stakeholders—from researchers to executives—the ability to adapt to these dynamic changes will be crucial in shaping the future of drug development and patient care. In conclusion, these stories collectively paint a picture of an industry evolving through scientific breakthroughs while adapting through strategic business decisions. As new technologies integrate into this space alongside regulatory advancements in gene therapy, this period of transformation holds promising implications for addressing unmet medical needs and enhancing therapeutic outcomes globally.Support the show

-Gavin Newsom's alleged “behest payment” system gets a thorough airing as Rob compares California politics to a loyalty rewards program where donations seem to arrive shortly before government favors conveniently appear.  -Philip Patrick (Birch Gold Group) joins Rob to discuss the economic impact of the emerging Iran agreement, interest-rate policy, inflation, debt, and precious metals. Patrick explains that while easing tensions in the Middle East may temporarily calm markets, the long-term drivers supporting gold remain America's growing national debt, deficit spending, and concerns about the purchasing power of the dollar. Today's podcast is sponsored by : PARAMOUNT PLUS - Don't Miss "The Agency." All episodes streaming June 21st on Paramount Plus RELIEF FACTOR - You don't need to live with aches & pains! Reduce muscle & joint inflammation and live a pain-free life by visiting http://ReliefFactor.com  BIRCH GOLD - Protect and grow your retirement savings with gold. Text ROB to 98 98 98 for your FREE information kit! To call in and speak with Rob Carson live on the show, dial 1-800-922-6680 between the hours of 12 Noon and 3:00 pm Eastern Time Monday through Friday… Musical parodies provided by Jim Gossett (http://patreon.com/JimGossettComedy) You can now WATCH and chat with The Rob Carson Show LIVE on Newsmax's social media channels (Facebook, X/Twitter, YouTube, Rumble) Listen to Newsmax LIVE and see our entire podcast lineup at http://Newsmax.com/Listen Make the switch to NEWSMAX today! Get your 15 day free trial of NEWSMAX+ at http://NewsmaxPlus.com Looking for NEWSMAX caps, tees, mugs & more? Check out the Newsmax merchandise shop at : http://nws.mx/shop Follow NEWSMAX on Social Media:  -Facebook: http://nws.mx/FB  -X/Twitter: http://nws.mx/twitter -Instagram: http://nws.mx/IG -YouTube: https://youtube.com/NewsmaxTV -Rumble: https://rumble.com/c/NewsmaxTV -TRUTH Social: https://truthsocial.com/@NEWSMAX -GETTR: https://gettr.com/user/newsmax -Threads: http://threads.net/@NEWSMAX  -Telegram: http://t.me/newsmax  -BlueSky: https://bsky.app/profile/newsmax.com -Parler: http://app.parler.com/newsmax Learn more about your ad choices. Visit megaphone.fm/adchoices

Barbara and Jacie wrap up their five-part Shoemaker Protocol series with Phase 5: Repair and Restore. This phase focuses on normalizing innate immune markers (MMP-9, C3a, C4a, and TGFb1) and restoring brain volume. They explain that low-starch/gluten-free diet helps bring down MMP-9, while persistently elevated C3a/C4a or TGFb1 often signal ongoing exposure, gut issues, tick-borne illness, or dental cavitations. The episode culminates with VIP (vasoactive intestinal peptide) nasal spray (the most anticipated step of the entire protocol!) which supports anti-inflammatory pathways, neurological function, and brain volume restoration over 6–12 months. For more information and support, join us at https://thecirsgroup.com TIMESTAMPS 00:00 Introduction: Phase Five 01:24 Medical Disclaimer 01:55 Innate Immune Markers and VIP Nasal Spray 02:50 Understanding MMP-9 05:14 C3a and C4a Markers 07:20 TGFb1 08:18 VIP Spray Treatment 10:34 Closing Thoughts For more information and support, join us at https://thecirsgroup.com Order Jacie's book! The 30 Day Carnivore Bootcamp: https://a.co/d/7MgHrRs The CIRS Group: Support Community: https://thecirsgroup.com Instagram: https://www.instagram.com/thecirsgroup/ Find Jacie for carnivore, lifestyle and limbic resources: Jacie's book on the Carnivore diet!  https://a.co/d/8ZKCqz0 Instagram: https://www.instagram.com/ladycarnivory YouTube: https://www.youtube.com/@LadyCarnivory Blog: https://www.ladycarnivory.com/ Find Barbara for business/finance tips and coaching: Website: https://www.actlikebarbara.com/ Instagram: https://www.instagram.com/actlikebarbara/ YouTube: https://www.youtube.com/@actlikebarbara Jacie is a Shoemaker certified Proficiency Partner, NASM certified nutrition coach, author, and carnivore recipe developer determined to share the life changing information of carnivore and CIRS to anyone who will listen. Barbara is a business and fitness coach, CIRS and ADHD advocate, writer, speaker, and a big fan of health and freedom. Together, they co-founded The CIRS Group, an online support community to help people that are struggling with their CIRS diagnosis and treatment.

Matthew "Oki" O'Connor is the CEO of Scientific Affairs at Cyclarity Therapeutics, a clinical-stage biotech building a new class of medicines designed not to slow the accumulation of vascular damage but to reverse it. Oki and Chris first crossed paths as postdocs at Lawrence Berkeley National Lab in the mid-2000s — Oki was in Irina Conboy's lab, not far from the late Judy Campisi's group, where Chris was then working on cellular senescence. After Berkeley, Oki spent nearly a decade running the research program at the SENS Research Foundation, the organization most identified with the "damage repair" framing of aging biology, before co-founding Cyclarity (then known as Underdog Pharmaceuticals) in 2019 to translate one of SENS's most drug-tractable ideas into an actual molecule.When Oki was last on the show in March of 2023 (Episode 36), Cyclarity was deep in IND-enabling work and its lead asset, UDP-003, had only ever seen the inside of a mouse artery. At the end of that conversation, Chris asked what Oki hoped to be discussing the next time he visited. He answered, bluntly, that he wanted to be presenting human data. Last month, at the AHA Vascular Discovery Sessions, Cyclarity reported the results of their first-in-human Phase 1 trial of UDP-003 — a designed cyclodextrin that selectively binds 7-ketocholesterol, the oxidized cholesterol species that drives foam cell formation and arterial plaque. He's back to discuss what the drug actually did when it went hunting for 7KC inside a living human being.In this episode, Chris and Oki cover the unmet need that lipid-lowering drugs — statins, PCSK9 inhibitors, the coming Lp(a) agents — still don't address: none of them remove the damage already sitting in an artery wall. Oki explains the basic chemistry of 7-ketocholesterol and why macrophages, lacking the machinery to recycle it, collapse into foam cells and seed the necrotic core of advanced plaque. They walk through the engineering of UDP-003 as a dimeric beta-cyclodextrin "double cone" tuned for a single oxidized cholesterol species, the design of the 72-volunteer Australian Phase 1, and the exploratory pharmacodynamic readout that has the field's attention: dose-dependent urinary excretion of 7KC, stoichiometric with drug, cleared within a day. The conversation then turns to the 150-patient Phase 2 plan in coronary artery disease patients with plaque imaging as the primary biological readout, the funding math that stands between Cyclarity and that trial, the platform's reach into NASH, vascular dementia, AMD, and aging itself, and how all of this descends from the SENS damage-repair philosophy that Oki has been carrying since LBL.The Finer Details:- Why current standard of care is not enough — statins, PCSK9 inhibitors, GLP-1s, and the soon-to-arrive Lp(a) lowering agents all act by slowing the accumulation of arterial damage, not by reversing what's already there; despite 30 years on the market, statins have never demonstrated an all-cause mortality benefit in a clinical trial, and even the best statin imaging data shows only 1–2% plaque volume regression at very high doses in a subset of patients- The scale of the problem — atherosclerosis is estimated to contribute to roughly 40% of all human deaths once heart attack, stroke, and a surprisingly large COPD contribution are risk-adjusted in, on top of an enormous morbidity tail that includes angina, peripheral artery disease (up to and including amputation), and a growing case for vascular dementia as an undercounted driver of cognitive decline- The biology of 7-ketocholesterol — when an oxygen free radical reacts with cholesterol, it preferentially attacks the 7 position, and a second oxidation step locks the molecule into 7KC, a stable toxic species cells were essentially never equipped to recycle; it builds up in long-lived cells like macrophages, eventually shutting down their ability to traffic lipids back to the liver via HDL and converting them into foam cells that seed soft plaque and, over years, the necrotic core of advanced lesions- The molecular design of UDP-003 — cyclodextrins are naturally occurring carbohydrate rings; the beta size fits half a cholesterol molecule, and Cyclarity's in silico work showed that two beta-cyclodextrins facing wide-side to wide-side form a "double cone" that can fully encapsulate a single cholesterol; engineered correctly, that wrapper can be made selective for 7KC over native membrane cholesterol, which is what gives the drug its therapeutic window- The Phase 1 trial design and result — a traditional 72-volunteer safety study in Australia, split between single ascending dose and multiple ascending dose arms, escalating up to six doses at what Cyclarity believes will be the efficacious level; no serious adverse events, no bioaccumulation, drug excreted essentially completely in the urine (as predicted preclinically), and — the headline exploratory endpoint — dose-dependent urinary 7-ketocholesterol appearing on the same timescale as the drug, consistent with one molecule of UDP-003 binding one molecule of 7KC and leaving the body together- What the urinary 7KC readout can and cannot tell you — the easiest 7KC to mobilize is the free pool in circulation, but there is not nearly enough of it floating in the bloodstream to account for what came out in urine, which means the drug is reaching deeper compartments; how much is coming from vessel wall plaque versus liver versus other peripheral tissues will require the imaging endpoints of Phase 2 to answer- The Phase 2 plan — 150 coronary artery disease patients (the coronary being, as Oki puts it, the artery most likely to kill you), with baseline plaque imaging, a year of dosing, and a repeat scan; safety and PK continue, inflammatory biomarkers come on, and plaque volume change is the prize — for context, a 1% change in plaque volume is associated with roughly a 20% change in next-year risk of heart attack or stroke- The funding math and the platform — Cyclarity has raised $33M to date and needs roughly $45M more to run the Phase 2, with Phase 3 cardiovascular outcomes trials running into the hundreds of millions and likely requiring a pharma partner; beyond atherosclerosis, 7KC is elevated in NASH livers, in Alzheimer's brains, and in the retinal cells that die in age-related macular degeneration, and the underlying chemistry — designed binders that drag a specific toxic molecule out of the body — is meant to generalize into a pipeline against other accumulated damage species, the direct intellectual descendant of the SENS damage-repair programQuotes:"Atherosclerosis, or the plaque that builds up in your blood vessels in your arteries, is estimated to cause approximately 40% of all human death.""When [the macrophage] eats up too much oxidized cholesterol, it just accumulates it… And that's when you get this transition to these kind of monster blob cells called foam cells.""One molecule of our drug is supposed to bind one molecule of 7-ketocholesterol and then go away and never be seen again. You excrete both of them together.""A 1% change in plaque volume is associated with a 20% risk in the next year of your probability of having a heart attack or a stroke.""You pick one target at a time, you do it well, and you take it all the way to the clinic and hopefully prove that you can actually cure patients, help them get better, help their plaque shrink away, and prove that this approach can work."Links:Cyclarity Therapeutics: https://cyclarity.com

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and strategic maneuvers transforming the industry landscape. Intellia Therapeutics has made remarkable progress with lonvoguran ziclumeran, achieving an 89% reduction in attack rates in its Phase 3 trial for hereditary angioedema. This gene therapy utilizes CRISPR technology combined with antisense oligonucleotides, highlighting the transformative potential of genetic editing techniques. The success of this approach underscores CRISPR's promise in offering long-term solutions through single-dose treatments, setting a benchmark for future therapies targeting genetic disorders. Regulatory dynamics are also shifting, as evidenced by Germany's move to abandon its variable drug discount plans after major pharmaceutical companies like Boehringer Ingelheim and Eli Lilly withdrew investments. This decision highlights the ongoing complexities and challenges in drug pricing policies, which are vital for maintaining equitable access to medications while ensuring economic sustainability for pharmaceutical companies. On the manufacturing front, Recipharm is investing significantly to upgrade its U.S. production capabilities in response to rising demand for biologics. This trend reflects an industry-wide push towards expanding biologic drug manufacturing infrastructure, driven by biologics' potential for personalized medicine applications. Similarly, Eisai has secured a UK government grant to expand its Hatfield plant for monoclonal antibody production, while Johnson & Johnson is investing $1 billion to enhance Acuvue contact lens production. These expansions illustrate how major companies are bolstering manufacturing capabilities to support strategic growth and meet increasing product demand. Merck & Co.'s partnership with Protillion Biosciences, valued at $510 million, exemplifies the growing integration of AI/ML technology in drug discovery. This collaboration aims to leverage Protillion's Prot-map protein design platform to enhance data generation and accelerate biologics development, illustrating how artificial intelligence is streamlining drug discovery processes. In clinical trials, promising developments continue to emerge. Spyre Therapeutics reported that SPY002 met its Phase 2 primary endpoint in ulcerative colitis with anti-TL1A results, positioning it as a potential leader in autoimmune disease therapies. Edgewise Therapeutics also presented supportive Phase 2 data for EDG-7500, which targets hypertrophic cardiomyopathy, paving the way for Phase 3 trials. These advancements highlight the potential of small molecules and combination therapies in addressing complex diseases. Additionally, Alto Neuroscience's ALTO-207 has shown benefits for anhedonia in major depressive disorder patients through independent Phase 2 data. This underscores ongoing progress in treating neurological disorders using innovative combinations of established compounds like dopamine agonists and ondansetron. The landscape is further enriched by Moderna's expansion plans. Anticipating up to three new product launches between 2027 and 2028, Moderna is restructuring its operations under new leadership. This strategic realignment aims to streamline processes across commercial, manufacturing, and R&D divisions ahead of significant product launches. Regulatory collaboration is advancing, with the FDA and UK's Medicines and Healthcare products Regulatory Agency (MHRA) initiating a new liaison program. This initiative aims to harmonize regulatory responses across borders, potentially accelerating drug approvals.Support the show

This week we talk about LDL, HDL, and cardiovascular issues.We also discuss one-time therapies, statins, and pharmaceutical economics.Recommended Book: Blood by Dr. Jen GunterTranscriptCholesterol is the most common type of what's called a sterol, which is a type of steroid, but also structurally technically an alcohol. But functionally, and classified by scientists, cholesterol is a lipid, which in this case is similar to a fat in all but how the body uses it. Cholesterol is the type of sterol most commonly found in animals—other types are found in plants and fungi—and its function, and this is where it varies from fats, which are used to store energy, is to basically help hold the cell membrane together, and it also serves as an intracellular messenger.Cholesterol is especially prevalent in the brain and spinal cord of animals, but it's found throughout their bodily tissues, as well, and again, it's vital for holding everything together and helping things communicate, in addition to being a precursor for vitamin D, steroid hormones, and bile.You want to have cholesterol, then, as without it you would be dead.Too much cholesterol in the blood, however, can also make you dead, especially when it's bound to what's called low-density lipoprotein, or LDL, as that contributes to cardiovascular disease like heart attacks and aneurysms, which can massively impact one's overall wellness and quality of life, and at extremes lead to the whole system shutting down as a consequence of heart attack, stroke, and the like.A lot of things can contribute to the development of cardiovascular disease, including habits like smoking, genetic predisposition, and the enthusiastic consumption of alcohol and unhealthy foods. But high blood cholesterol, of the LDL variety, is one of the top contributors, as these low-density clusters of lipoprotein can clog the pathways that blood takes throughout our bodies. Other, denser types of lipoproteins, HDLs, can clear it, like a heavier, denser substance pushing through clogs of less-dense materials that are gumming up a pipe, but LDL is at times accumulated as a result of consuming delicious but unhealthy foods, which are hard to avoid, and for some people the only consistently available and affordable foods; and for other people LDL accumulates as a result of their genetic predispositions—two things that are devilishly difficult to change.What I'd like to talk about today is a new type of therapy that may be very good news for people who struggle with the accumulation of LDL, and why this is being seen as very good news more broadly, at the scale of entire nations, as well.—Pharmaceutical company Eli Lilly is testing a new, experimental drug called VERVE-102 which is a one-time infusion that is currently administered over the course of about four hours, and once completed, it turns off a gene called PCSK9, which is responsible for making a protein that regulates cholesterol levels in humans.As I said, this drug is still being tested, so these are early results. But in a study of 35 people with high cholesterol levels, high levels of LDL or LDL-C, which is short for lipoprotein cholesterol, they found that this infusion, which again, is a one-time treatment, so get it once and then theoretically at least you never have to get anything done ever again, it reduced those LDL and LDL-C levels by as much as 62%, and that reduction was maintained a year and a half after the infusion; that's how far out they're retested so far, and the hope is that each retest will continue to show the same.On the strength of those very promising results, a Phase 2 study has been planned by the end of 2026, and the US Food and Drug Administration, the FDA, previously fast-tracked this existing study, because of the promise and potential this drug already demonstrated in early studies; all of which is considered to be very significant progress and possibility.To understand that significance, though, it's useful to know some health stats. And I'm going to focus on the US here, as that's where this drug is being developed, but many wealthy countries have similar stats, at least in terms of cardiovascular disease struggles.As of 2024, which is the last year we had good, cohesive data on this in the US, it was estimated that about 11-12% of the US adult population has high cholesterol levels. This typically doesn't come with any symptoms, but it can contribute a higher risk for all those cardiovascular diseases, including heart attack and stroke. A further 86 million US adults have borderline or elevated cholesterol levels, which can easily tip higher, but also, even in that existing, elevated state, contribute to negative cardiovascular outcomes.There are treatments for high cholesterol, the most common of category of which are called statins, which reduce the production of LDL by inhibiting an enzyme that produces cholesterol in the body.Unfortunately, these drugs do come with some usually minor side effects, which can cause patients to stop using them, and they have to be taken daily, ideally at the same time each day. That necessity for consistency leads to a lot of incorrect or incomplete usage, which reduces the effectiveness of these drugs. But it's also estimated that only about 54.5% of US adults who would benefit from statins are currently taking one—so that's people who could benefit and who have it prescribed, and then within that number are all the people who are taking this drug incorrectly or incompletely, reducing the effectiveness. So a relatively small number of people who should probably be on these things are getting the full benefit they offer because of the nature of the drug.And that's not great, because in the US alone, heart disease is the leading cause of death for pretty much every adult demographic; men, women, people of most racial and ethnic and economic groups, you name it, heart disease is the biggest threat to their lives.One US citizen dies every 34 seconds of some kind of cardiovascular condition, and as of 2023, 1 in every 3 deaths in the US was caused by the same, adding up to just over 919,000 people that year.Between 2021 and 2022, alone, the cost of services and medications related to heart disease added up to more than $168 billion; again, that's just in that period, and just in the US.And once more, these are ailments that are caused or heavily influenced by high levels of cholesterol, which are themselves amplified by common lifestyle choices, environmental factors that are hard for many people to avoid, and just by raw, dumb luck because of genetics.This treatment category, then, is being seen as a pretty big deal because a one-time infusion means those who receive it don't have to remember to take a pill every day at the same time, and won't experience those statin-based side-effects.It also means that people who are currently costing the medical system a bunch of money each year, because they need treatments for all the issues they suffer as a result of high cholesterol, will suddenly cost the system a lot less money, for treatments and medications. Not for nothing, their health and quality of life will likely improve as well. So in addition to having better, healthier outcomes personally, their cost to healthcare systems will drop.Eli Lilly's drug isn't the only one currently working its way through clinical trials, either.Amgen is working on a similar treatment, and Novartis and Ionis Pharmaceuticals have drugs that are even further along in the process, their medicines that cut heart attacks, strokes, and cardiovascular deaths could be approved by the FDA as soon as next year.There are a lot of caveats worth noting here, including that the science is still out as to whether this approach, silencing proteins that lead to the creation of more LDL and a similar substance called Lp(a)—which is more dangerous because it's stickier and thus more likely to get stuck in important blood pathways, and it's also more likely to be caused by genetics than lifestyle—the word is still out on whether reducing these things in the body actually reduces hearth attacks and stroke.Some people have had this particular risk variable dramatically reduced, but have still suffered from cardiovascular events, which raises the question of whether this path is the right one to take in trying to reduce this category of health issues; the correlation between LDL and heart attacks and strokes might not be a clear-cut as long assumed.There's also the issue of price. Drug-makers are economically incentivized to sell treatments over cures, because that means they can continue selling their product over time, potentially for the life of the patient, and a cure, in contrast, is a one-time hit that in theory should alleviate the need for future treatment.There's a chance, then, that the drug-makers will decide they need to make these one-hit treatments really, really expensive in order to make their R&D dollars back and to make the kinds of profits their investors expect from them. That could then reduce the potential audience for these treatments, even if they are effective, and could further slow their deployment and future research in this space.If these trials continue to go well, though, there's a good chance that this combination of similar but distinct treatment types will provide a more sustainable alternative to current options, and that, like the recent bogglingly rapid and widespread deployment of GLP-1 treatments for all sorts of issues, could lead to a new paradigm in this facet of the medical world.Show Noteshttps://en.wikipedia.org/wiki/Cholesterolhttps://en.wikipedia.org/wiki/Cardiovascular_diseasehttps://en.wikipedia.org/wiki/High_cholesterolhttps://pmc.ncbi.nlm.nih.gov/articles/PMC10982736/https://www.cdc.gov/heart-disease/data-research/facts-stats/index.htmlhttps://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1https://www.ama-assn.org/public-health/chronic-diseases/what-doctors-want-patients-know-about-high-cholesterolhttps://en.wikipedia.org/wiki/Statinhttps://pubmed.ncbi.nlm.nih.gov/42187087/https://abcnews.com/GMA/Wellness/new-drug-game-changer-people-high-cholesterol/story This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit letsknowthings.substack.com/subscribe

It's In The News - a look at the top diabetes stories and headlines happening now!   Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Episode transcript: fall Detroit and Seattle.   Okay.. our top story this week: XX The FDA approved Tzield for use in stage 3 T1D – that's what we used to just call type 1. It's the stage where the body can no longer produce enough insulin on its own to manage blood sugars you need to start insulin. This approval is for kids ages 8-17 within 8 weeks of a stage 3 T1D diagnosis. It comes after the PROTECT trial and it's the first approval of a disease-modifying therapy for stage 3 T1D. https://www.prnewswire.com/news-releases/breakthrough-t1d-celebrates-approval-of-tzield-for-use-in-stage-3-type-1-diabetes-in-the-us-302799532.html XX Encouraging results from a small study of islet cell transplantation in people with type 1 where now all 12 participants in the trial are currently living without external insulin after receiving transplanted insulin-producing islet cells.   The study, led by researchers at the University of Chicago, tested an experimental immune therapy called tegoprubart Te-GO-Proo-Bart. The drug is designed to prevent the body from rejecting transplanted cells while avoiding some of the side effects associated with standard anti-rejection medications. You've probably heard about this as the Eledon study – many of the participants have been very active on social media. It was presented at ADA. transplants.https://www.breakthrought1d.org/news-and-updates/tegoprubart-islet-transplant-all-participants-off-external-insulin/ XX New data suggest that acmopatide (ack-MOW-puh-tyd) (CT-868), an experimental once-daily dual GLP-1/GIP receptor agonist, may help people with type 1 diabetes improve blood sugar control, lose weight, and reduce insulin use. Across all doses, participants lost up to 7% of their body weight and reduced insulin use by as much as 15%. The study lasted just 16 weeks, so researchers say longer-term data will be needed to determine whether the benefits can be maintained and whether lower insulin requirements can be achieved without increasing the risk of hypoglycemia. XX A new combination therapy that pairs an amylin analog with semaglutide improved both blood sugar levels and weight loss in several groups of people with type 2 diabetes. The once-weekly injectable, known as CagriSema (KAG-ruh-SEM-uh), was evaluated in three Phase 3 REIMAGINE studies. In people early in the course of type 2 diabetes, researchers reported A1C reductions of up to 1.8 percentage points and significant weight loss compared to placebo after 40 weeks of treatment. Investigators also noted improvements in several cardiometabolic risk factors, including blood pressure. https://www.medpagetoday.com/meetingcoverage/ada/121658 XX Stelo for kids is now FDA cleared.. the over the counter Glucose Biosensor System is now approved for children as young as 2 years old who do not use insulin. The FDA identified pediatric prediabetes as a growing public health concern motivating the expanded indication, noting OTC CGMs can help younger users and their caregivers build glycemic awareness, track patterns in response to me https://www.hcplive.com/view/fda-clears-first-otc-glucose-monitor-for-children XX Insulet presented new data from its STRIVE and EVOLUTION 3 studies showing improved glucose control with its next-generation Omnipod 6. That's , the company's upcoming hybrid closed-loop system for people with type 1 and type 2 diabetes. The main difference between the Omnipod 6 and Insulet's current Omnipod 5 patch pumps is that the new system has a lower glucose target of 100 mg/dL and better Bluetooth connectivity Insulet also shared progress on a fully closed-loop system designed specifically for type 2 diabetes. It  does not require carb-counting or insulin bolusing ahead of meals. Physicians also don't need to program the starting settings.   XX Abbott shared new research highlighting challenges in identifying and managing diabetic ketoacidosis (DKA). The studies coincide with the company's development of Libre Duo, a dual glucose-ketone sensor that continuously tracks both measurements. Abbott reported that DKA can be difficult to recognize when patients first arrive at the hospital, based on data from more than 100,000 people. The company has submitted the dual sensor to the FDA and recently received CE Mark approval in Europe. More news from ADA including info from Dexcom, Sequel, Sensonics and the world loses a tireless T1D advocate.. that's all to come right after this. --   Back to the news.. XX   Dexcom announced its acquisition of Nutrisense, a company that combines continuous glucose monitoring with nutrition coaching and behavioral support. At ADA, the company also presented results from the CONNECT study showing significant A1C reductions and improved glucose control in people with type 2 diabetes not using insulin. The findings add to growing evidence supporting CGM use beyond intensive insulin therapy. We did an episode with CEO Jake Leach at ADA about these announcements as well as updates on G8, their hospital product and much more. XX Sequel Med Tech reported positive clinical results evaluating its twiist automated insulin delivery system in people with type 2 diabetes. The study showed improvements in A1C and time in range over 13 weeks XX Senseonics presented new real-world data supporting the performance of its Eversense 365 implantable CGM. The analysis included more than 12,000 sensors and demonstrated sustained accuracy and effectiveness in both open-loop and automated insulin delivery settings. Researchers also evaluated Eversense use with Sequel Med Tech's twiist system. The findings support broader use of long-term implantable CGM technology.   -- MiniMed used ADA 2026 to spotlight two recently cleared diabetes management systems. The MiniMed Flex pump offers a smaller, smartphone-controlled insulin pump option, while MiniMed Go combines the InPen smart insulin pen with Abbott's Instinct sensor. The products received FDA clearance earlier this year. XX Tandem Diabetes Care highlighted data supporting the use of its Control-IQ automated insulin delivery technology during pregnancy. Results from the CIRCUIT trial showed users spent approximately three additional hours per day in the recommended pregnancy glucose range compared with standard therapy. The findings helped support recent regulatory approvals for pregnancy use in both Europe and the United States. Tandem also expanded indications for adults with type 2 diabetes. XX Beta Bionics presented real-world data from the first three years of iLet Bionic Pancreas use. The company reported a 25% improvement in time in range among users, along with positive feedback from clinicians about simplified diabetes management. The iLet system requires only a user's weight to begin therapy and eliminates carbohydrate counting. Beta Bionics also highlighted growing access to near-real-time outcomes through its public data dashboard. XX MannKind presented new findings supporting its Afrezza inhaled insulin at ADA 2026. A post-hoc analysis of the INHALE-1 study found that pediatric users reported greater treatment satisfaction compared with those using rapid-acting injected insulin. The results come shortly after FDA approval expanded Afrezza's indication to include children. We did a bonus episode with one of the lead investigators of the study that lead to that approval. XX Adaptyx presented early clinical data supporting a wearable sensor that continuously measures cortisol levels. The device successfully tracked cortisol changes during both controlled testing and overnight monitoring in first-in-human studies. Company leaders say cortisol plays a major role in conditions including diabetes, hypertension, and depression. The technology uses synthetic DNA-based molecular switches to generate real-time readings.   XX Biolinq shared new clinical findings for its Shine continuous glucose monitoring system. The needle-free device combines glucose monitoring with activity and sleep tracking .The system received FDA clearance in 2025. They're also looking at measuring lactate through the sensor. XX Long-time T1D advocate Kent Schnakenberg died last week. Schnakenberg was known in his community for using his love of bicycling to raise awareness of Type 1 diabetes. He also advocated for improving the lives of those living with the disease. Inspired by his niece, Michelle, who was diagnosed with juvenile diabetes when she was 13 years old, since 2014 he has traveled around the country cycling thousands of miles, speaking to hundreds and hundreds of kids and raising Money. According to Schnakenberg's family, he suffered a head trauma incident in his home on Wednesday. I spoke to Kent years ago – I believe the first year of the podcast. A sad loss but wonderful to see so many tributes and memories posted on social media in the last few days. https://diabetes-connections.com/john-costik-co-creator-of-nightscout-team-schnak/ https://www.wibw.com/2026/06/12/team-schnak-founder-kent-schnakenberg-passes-away/ XX And finally. Alexander Zverev (ts-ver-uhv) won the French Open, his first Grand Slam title. He lives with type 1, he paused a couple of time to check his blood sugar. He was diagnosed at age 4 and partners with Medtronic. "Becoming a professional tennis player was always my dream," Zverev shared in an article posted by Medtronic. "Early on, I was told that competing at the highest level with diabetes was impossible — but my family and I refused to accept that. That's why I'm partnering with Medtronic Diabetes: I want every person with diabetes to feel empowered to live the life they want." He also has a foundation committed to children with type 1 diabetes. Among other things, the life-saving insulin and other essential drugs are provided – also in developing countries." https://www.mensjournal.com/news/alexander-zverev-diabetes-wins-french-open-2026-medical-condition

The fight fares poorly for the Allies in Norway and into this front our party is sent - this time to try to find the injured Crown Prince of Norway before the Nazis can.  They will need to link up with a new contact and make their way through treacherous, enemy-controlled waters in occupied Trondheim and find the Norweigan resistance before time runs out... Theme song for London Calling! is "Dark Ritual" by Adrian von Ziegler. More from this amazing composer at https://adrianvonziegler.bandcamp.com/  All other scores are used with permission from Adrian von Zielger and Antti Martikainen https://anttimartikainen.com/  Intro song is "Walkin' with Michael Douglas" by A Wilhelm Scream; more here https://www.awilhelmscream.com/ Special thanks to David of the 2W12 - Die besten Spielleiter der Welt podcast!  Check them out here 2w12.podigee.io and on youtube here https://www.youtube.com/@2w12podcast Please consider supporting us on Patreon at www.patreon.com/nastygram - it would mean the world to us!  (And you get some pretty cool stuff including bi-weekly bonus episodes!  Find us on Facebook at www.facebook.com/nastygram  and our group is at https://www.facebook.com/groups/865467380821766; we are @nastygramrpg on both Instagram and Twitter and on Tik Tok at @nastygram.rpg

Dr. Tony Ebel breaks down the updated four-phase clinical healing model used at PX Docs — and why the sequence you follow matters more than almost anything else. He explains why so many kids get stuck or even get worse when families skip ahead to detox, supplements, or movement therapies before the nervous system foundation is repaired first. Dr. Tony also introduces Kingdom Health Sciences, a new pediatric supplement line built specifically for perfect storm kids, and explains exactly when and how to use it in the healing journey.-----Links & Resources:Learn more about the 4 Phases of Healing (and where your child is) HERE.Learn more about the supplements discussed in this episode HERE.Learn more about the INSiGHT Scans HERE.Episode Reference: The Perfect Storm Introduction [Apple/Spotify]-----Key Topics & Timestamps01:00 The #1 question parents ask once results begin 03:00 Dr. Tony shares his son's miracle story07:30 Why the motor system is where the storm actually lives 13:00 Proof the storm didn't start with toxins — parents who've done it all15:00 Why skipping phase one can make kids worse, not just stuck 20:00 Why sequence and timing matter more than any single intervention 24:00 The two signs your child is ready to move to phase two and three 27:00 Why the bad news on the INSiGHT scans is actually the best news 43:00 Phase three remediation: gentle always beats aggressive 50:00 How Kingdom Health Sciences was born and what makes it different-- Follow us on Socials: Instagram: @pxdocsFacebook: Dr. Tony Ebel & The PX Docs NetworkYoutube: The PX DocsFor more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care.Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click Here

Today we'll dive into the Weekly Top 3 with Brad Keithley from Alaskans for Sustainable Budgets. This weeks topics: There's a reason the Bullet Line (now, Phase 1) has never been built; does AKLNG change that? What are we really setting up with the #AKLNG bill; Why we should focus on a federal budget issue. Then in hour two I'll recap with some of my thoughts and then we'll finish up with our local PMA guru Chris Story.

Traumaheilung sieht von außen oft ganz anders aus, als sie sich von innen anfühlt – und genau darüber sprechen Matthias und ich in diesem Video ganz offen und persönlich. Wir erzählen, wie es bei uns wirklich war: wie eine Phase, die ich für einen spirituellen Aufbruch hielt, mich plötzlich in eine Tiefe geführt hat, aus der ich weder denken noch sprechen noch mich bewegen konnte. Wie mein Nervensystem in vollständige Erstarrung gefallen ist – und wie lange es gedauert hat, bis sich das langsam wieder lösen durfte. Matthias erzählt, wie bei ihm ganz frühe, frühkindliche Ebenen aufgebrochen sind und was es bedeutet, wenn der Körper plötzlich eine Geschichte zeigt, die man jahrelang nicht gespürt hat. Wenn du dich fragst, ob du irgendetwas falsch machst, weil es dir gerade so schwer fällt – dann ist dieses Video für dich. Den nächsten Schritt musst du nicht alleine finden. Der Morgenlicht-Quiz hilft dir herausfinden, was dein Nervensystem gerade braucht: https://kurse.leahamann.de/quiz

Is retatrutide, the new triple agonist GLP-1, the next big thing in weight loss (or even rapid fat loss)?That depends on how the drug works, what the results are, the reality between the headlines and the evidence, and what happens to your weight when you stop.This episode breaks down retatrutide, the GLP-1, GIP, and glucagon triple agonist behind the largest weight loss numbers ever recorded in this class. It covers the Phase 2 obesity trial and the Phase 3 Triumph results, plus why cross-trial comparisons to semaglutide and tirzepatide deserve skepticism.We examine the body composition data (or lack thereof), and why a bigger number on the scale just amplifies the stakes for muscle mass, weight regain, and the off-ramp. Especially relevant for adults over 40 who are taking, considering, or planning to come off a GLP-1.Enroll in Eat More Lift Heavy, the 26-week coached program where adults over 40 build the nutrition and training skills to preserve muscle, lose fat, and manage their physique for life, including support for lifestyle changes needed while taking GLP-1s (and to come off them if desired).Timestamps:0:00 - Retatrutide and the biggest question for GLP-1 users 3:08 - How this new triple agonist works 4:46 - Phase 2 and Phase 3 weight loss numbers 5:38 - Cross-trial comparisons and their limits 6:23 - Fat, muscle, and what the trial did NOT measure 8:30 - Strength training over 40 and accelerated muscle loss 10:07 - Building the lifestyle (alongside using the drug) 14:10 - Resistance training and protein 16:00 - Rate of loss on a powerful drug like retatrutide 17:30 - The off-ramp when you stop 18:23 - Weight regain and body fat overshooting 22:03 - Retatrutide access and the gray market 24:11 - Bonus: 3-question test to keep your resultsEpisode Mentioned:Sometimes More Is More (The Sedentary Lifter Problem)

▶ AUDIODROP 04: Remembering Who You Are There comes a point in every transformation journey where you realize the goal isn't becoming someone new. It's remembering who you were before the fear. Before the conditioning. Before the disappointment. Before the stories that convinced you that you weren't enough. In this special BOOM AudioDrop, Heather explores why you don't need fixing, how abundance is your natural state, the connection between belief and action, and why the most powerful shifts often begin with a simple change in perspective. Inside this episode: ✨ Why you are already whole, complete, and enough ✨ The difference between fixing yourself and remembering yourself ✨ How belief acts as a multiplier in every area of life ✨ The truth about effort, action, and receiving ✨ Why imagination is one of the most powerful tools for creating change ✨ How to begin aligning with a higher outcome today This is more than mindset work. It's identity work. It's learning how to stop living from old patterns and start living from possibility. Ready for the full BOOM experience? The complete BOOM: The Shift program includes guided workbook exercises, journal prompts, daily practices, AudioDrops, coaching lessons, and the full Get Unstuck Blueprint designed to help you shift patterns, create momentum, and build a life that feels aligned from the inside out. ✨ Get instant access: https://glitteru.com/boom All my love, Heather BOOM. ✨

Phase two of Predator Free Wellington's groundbreaking project to rid our capital of rats is well underway. They've learned a lot from their work on the Miramar Peninsula, but with this new chapter comes new challenges – not just backyards, but a hospital, and even a zoo! Charlie Dreaver meets some of the team out fighting this battle on multiple interesting fronts. Sign up to the Our Changing World monthly newsletter for episode backstories, science analysis and more.Learn more:The target for Wellington to become New Zealand's first predator-free city was announced by Conservation Minister Tama Potaka in March, as part of a Predator Free 2050 strategy update.In November last year the government added feral cats to the Predator Free 2050 list of targeted predators, likely in response to RNZ's In-Depth team's reporting about the destruction they cause, and a pre-election promise.Learn more about other large predator removal projects such as Predator Free Rakiura and Predator Free South Westland, and the plan to make Auckland Island predator free.Guests:Zara Koorey, Predator Free WellingtonJames Wilcocks, Predator Free WellingtonChirs Jerram, Te Nukuao Wellington ZooSally Bain, Predator Free WellingtonGo to this episode on rnz.co.nz for more details

Most hard conversations do not go wrong because of what gets said.They go wrong because the person went in without knowing what they actually needed to say. Or they said the hard thing and immediately walked it back. Or the other person got defensive and they lost their footing. Or the conversation ended without a close, a commitment, or any shared sense of what comes next.This week on Leading Yourself, Carolina gives you the framework she uses with every coaching client before a hard conversation, and goes deep into what actually goes wrong at each stage.In this episode:The four failure points in hard conversations, and why the conversation itself is almost never the problemPhase 1: Prep. How to get clear on the one thing you need to say, what you actually want to happen, and how to name the fear before it shows up sidewaysPhase 2: Delivery. How to open without apologizing or presenting evidence, what to do in the silence after you say the hard thing, how to stay in the room when the other person gets defensive or emotional, and how to come back when the conversation goes sidewaysPhase 3: Follow-up. How to close a conversation so it actually produces something, why follow-through signals whether the conversation was real, and how to read the check-in to find out what actually landedWhat the framework is actually for, and the change it produces over time beyond any single conversationThis episode stands completely on its own. If you know someone sitting with a hard conversation right now, this is the one to share.This week's practice: run the conversation you have been avoiding through the prep phase. Write it out, all three parts. Then identify which phase you personally tend to skip. That is where your work is.

Michael McFaul reflects on the collapse of the Soviet Union, recalling his time in Moscow in 1991 when he witnessed the transition from Gorbachev's reforms to Yeltsin's revolutionary phase. He argues that while the United States rightly supported Yeltsin, policymakers were too complacent, assuming democracy would consolidate organically without significant external investment. This "end of history" mentality led to a lack of political and economic support during Russia's vulnerable early years of independence. McFaul notes that failing to provide robust assistance to liberal reformers allowed for the eventual rise of Vladimir Putin. (3)1906

Bwaaaaah…. I missed the final 2 Faces of the Feminine! They’re Medicine Woman & Mother, which makes the 6 Faces of the Feminine…. Mother, Lover, Warrior, Medicine Woman, Dark Goddess & Mystic. Sabrina The “Line in the Sand” Has Been Drawn. Are You Ready? We are officially entering the “Setup Phase” for the most auspicious alignment of the year. If you've been feeling an inexplicable exhaustion, a “hanging on by a thread” sensation, or a deep soul-weariness—this is your antidote. In this transmission, Sabrina Lynn reveals the three-part shamanic arc of June 15th–21st. We are moving from the chaotic “Gemini Mind” into the deep, rooted power of the Body Temple as Chiron makes its fated move into Taurus. This isn’t just another weekly update; it's a sacred rights of passage into your Feminine Sovereignty. What you need to know for this Solstice Crossing: ✦ The Reinvigoration Portal: How to tap into the “Inexhaustible Life Force” during the Venus transits (Monday-Wednesday). ✦ Chiron in Taurus: A major shamanic shift that will define your safety and security until 2033. ✦ The Solstice Crossing: Why June 21st is a literal “Line in the Sand” for leaving the old chapter behind. ✦ The July “Cauldron of Magic”: Why this week’s “Temple Preparation” is critical for receiving the “Jupiter on Crack” miracles coming next month. The world is changing, and the “Old Ways” of doing are crumbling. It's time to stop fighting and start embodying. Feminine Embodiment Resources: Bones Membership ($59): Your go-to for coming out of anxiety and softening into receptivity. The June workshop: A Return to Magic is the perfect practice for the “setup phase” for July. → Instant Access  Body Wisdom Activation ($47): A foundational practice to open your chakras and allow life force to flow—essential for Monday's Uranus transit. →  Lifetime Access Mary Magdalene Journey ($197): A sacred initiation into the higher heart. Open the dormant gifts of your past and align with the frequency of Divine Love that the world is starving for right now. Open until June 21st → Details here The Lover Bundle (Get 3 for the price of 2): Includes deep-dives into the Venus, Mary Magdalene, and Lalita archetypes to help you embody the “Lover” and “Mystic” faces of the feminine. Open until June 21st → Details here Persephone Retreat: A seven-part initiation to help you move from “adolescent” to “Queen” energy, aligning with the Venus-Pluto opposition. Open until June 21st → Details here Listen to “Something Is Coming in July… This Week Prepares You For It “ podcast here… Topics Explored in “Something Is Coming in July… This Week Prepares You For It” podcast: (Times based off audio version) Transmission Chapters (00:00) – The Line in the Sand: June 15th-21st (01:38) – Phase 2: Chiron's Shamanic Shift into Taurus (02:57) – The Nodes of Fate & Soul Fulfillment (04:30) – Why We're Skipping the Charts Today (Audience Request!) (05:25) – Monday-Wednesday: The Venusian Gifting Period (07:52) – The Feminine Art of Receiving & Environment (09:50) – Overcoming Anxiety & The “Bones” Medicine (12:03) – Magnetizing vs. Repelling: Your State of Being (14:50) – Monday: Inexhaustible Life Force (Venus & Uranus) (18:03) – Tuesday: The Feminine Mystic & Mary Magdalene (24:44) – Wednesday: Becoming the Queen (Venus Opposing Pluto) (30:11) – Friday: Chiron into Taurus & The Wound of Embodiment (37:54) – Safety, Security & Material Objects as Shamanic Tools (40:33) – Friday: Kali Conjunct Mars – Slaying the Ego (43:05) – Saturday: Sedna & The Deepest Depths of Self (45:36) – The Solstice: Your Ritual of Crossing (48:17) – Looking Ahead: The July “Cauldron of Magic” You can leave a comment or question for Sabrina on the YouTube version of this episode. Listen to after “Something Is Coming in July… This Week Prepares You For It”: A Higher Timeline Is Opening… What You Choose This Week Matters (June 8–14) June Is Changing the Rules: The Return of Magic 10 Feminine Truths I Wish I Knew Sooner STAY CONNECTED ReWilding Weekly (free, embodied astrology)  IG  Website  Disclaimer: Educational/spiritual perspectives; not medical/mental-health advice. #2025Shift #NewHuman #SpiritualAwakening Welcome to ReWilding with Sabrina Lynn & ReWilding for Women! A gifted facilitator of revolutionary inner work and the world's leading archetypal embodiment expert, Sabrina Lynn is the creator of the groundbreaking ReWilding Way and founder of ReWilding For Women. Sabrina has led more than 100,000 people through programs based on the ReWilding Way, a modality of healing and awakening that strips away the false, the deep wounds from early life, and the fears that hold people back, to reveal their true and unique soul light and help them build their innate capacity to shine it in the world. Her work includes in-person retreats and events, the monthly ReWilding Membership, Living Close to the Bone, Priest/ess Trainings, Mystery Schools, the ReWilding with the Archetypes, and the wildly popular 6 Faces of the Feminine workshop series. Welcome to ReWilding! The post 386 – Something Is Coming in July… This Week Prepares You For It appeared first on Rewilding for Women.

Episode 399 reviews Phase 2 of Season 15 and introduces the Motivation Loop — the sequence of meaning, belief, attention, action, reward, and recovery that drives sustained effort. The episode explains common loop breakers (loss of meaning, negative thoughts, distracted attention, too much challenge, poor recovery, and no visible progress) and how to diagnose which link is failing. Practical takeaway: identify your gap, reconnect purpose, protect attention, celebrate small wins, and balance challenge with recovery to keep motivation alive. In This Episode 399, We Will Cover: ✅ The Motivation Loop — what it is, why it matters, and how it influences behavior, focus, effort, and achievement. ✅ What Keeps the Loop Alive — the role of meaning, belief, attention, action, reward, recovery, and growth. ✅ What Breaks the Loop — how loss of meaning, negative thoughts, distraction, lack of progress, poor recovery, and burnout weaken motivation. ✅ The Neuroscience of Motivation — why the brain repeats what it rewards and how dopamine reinforces behavior. ✅ The Difference Between Challenge and Burnout — finding the sweet spot where effort creates growth instead of exhaustion. ✅ My Personal Motivation Loop Story — how I watched my own loop begin to break in real time while pushing too hard with hiking and what I learned from it. ✅ How to Repair a Broken Loop — practical strategies to restore motivation before burnout takes hold. ✅ The Anterior Mid-Cingulate Cortex (AMCC) — the brain region associated with persistence, self-regulation, resilience, and doing hard things. ✅ Why Doing Hard Things Grows the Brain — how meaningful challenges strengthen the neural circuits responsible for sustained effort. ✅ Finding Your Gap — using our Brain's Operating System framework to identify where your system may be out of alignment. ✅ The Biggest Lessons from Phase 2: Neurochemistry & Motivation — insights from Bob Proctor, Dr. Caroline Leaf, Dr. John Medina, Dr. Anna Lembke, Dr. Chuck Hillman, and Friederike Fabritius. ✅ What's Next — a preview of Episodes 400 and 401 on Leadership and Trust, and our transition into Phase 3: Movement, Learning & Cognition. Key Question of the Episode "When motivation begins to disappear, have we lost our drive—or is there simply a broken link in the loop?" Aha Moment The goal isn't to push harder. The goal is to identify the broken link, repair it, and keep the loop alive. EP 399: The Motivation Loop: What Keeps It Going—and What Breaks It? Welcome back to the Neuroscience Meets Social and Emotional Learning Podcast. This week, we're wrapping up Phase 2: Neurochemistry and Motivation. Over the past several months, we've explored some of the most important drivers of human behavior, attention, effort, learning, and performance. Through the work of Bob Proctor, Dr. Caroline Leaf, John Medina, Dr. Anna Lembke, Chuck Hillman, and Friederike Fabritius, we've been focused on one fundamental question: What drives sustained effort and forward movement? Today, I want to zoom out and connect everything we've learned into one simple framework: The Motivation Loop. More importantly, we'll look at: What keeps the loop going What causes it to break How we can strengthen it over time And why doing hard things may actually help grow parts of our brain responsible for persistence and self-regulation. The Brain's Operating System of Human Performance Before we dive into the Motivation Loop, let's remember what we've covered so far. One of the biggest insights from neuroscience is that high performance doesn't happen in one part of the brain. It happens through a sequence. Just like a computer has an operating system, our brains have an operating system for learning, achievement, and human performance. Over the past several months, we've been building that system one phase at a time. Phase 1: Regulation & Safety REGULATE The first question we asked was: "Is the nervous system safe enough to learn?" Before motivation... Before focus... Before performance... The brain must first feel regulated. Through guests like Bruce Perry, Kristen Holmes, Antonio Zadra, and Sui Wong, we learned that: Sleep matters Recovery matters Rhythm matters Our Stress levels matter A dysregulated brain struggles to learn. No regulation. No learning. Phase 2: Neurochemistry & Motivation ENGAGE Once the brain is regulated, we move to the next question: "What drives behavior, focus, and sustained effort?" This is the phase we've just completed. We explored: Dopamine Belief Thought patterns Attention Reward Burnout Energy And perhaps the biggest lesson from this phase was: The brain repeats what it rewards. This became the foundation of what I've called: The Motivation Loop: What Keeps the Loop Going? Looking at this graphic, notice the green side first. The healthy loop begins with: Meaning and Purpose When we know why something matters, effort becomes easier to sustain. This was Bob Proctor's message and the message that launched author Simon Sinek's entire career (Knowing Your Why). People can tolerate enormous challenges when the goal is meaningful. Example: Learning a New Skill Imagine someone deciding to learn a new language. At first: Progress is slow. Mistakes are frequent. The work feels uncomfortable. But they have a purpose. Maybe they want to connect on a deeper level with family. Maybe they want to travel. Maybe they want a new career opportunity. Purpose keeps them engaged long enough to continue with the hard work.   Belief Shapes Thought If I believe I can improve, my thoughts become more constructive. This was Dr. Caroline Leaf's work. Our thoughts influence our neurochemistry. Positive thoughts don't guarantee success. But they keep us moving toward it. Attention Drives Growth This was John Medina's contribution. Attention determines what the brain decides matters. The brain learns what we repeatedly focus on. What we attend to, we strengthen. Action Creates Progress Once attention is focused, behavior follows. We study. We practice. We train. We learn. Reward Reinforces Behavior This was Dr. Anna Lembke's work. The reward doesn't have to be huge. Sometimes it's simply noticing progress. The brain says: "That effort produced a result." And the loop continues. Example: Exercise A person begins walking 20 minutes every day. Week 1: No major changes. Week 2: Energy improves. Week 3: Sleep improves. Week 4: Resting heart rate begins dropping. The brain notices progress. The effort feels worthwhile. The loop strengthens. The behavior repeats. We have spent a lot of time on understanding how to keep the loop from breaking. How the Loop Breaks Now let's look at the red side. How the loop breaks. The loop rarely breaks all at once. Usually one link weakens first. Then the others follow. Loop Breaker #1: Loss of Meaning What Happened? A student studies only to pass a test. The test ends. The reason disappears. Motivation disappears. The loop breaks because there is no longer a compelling "why." What Could Have Prevented It? Reconnect to purpose. Instead of: "I have to study for this test." Shift to: "I'm building skills for the future version of myself." Bob Proctor taught us that goals are not just about achievement. They're about growth. Loop Repair Ask: "Why does this matter beyond today?" When meaning returns, motivation returns.   Loop Breaker #2: Negative Thought Patterns What Happened? Someone starts a health journey. After a difficult week they think: "I'm failing." "Nothing is changing." "I'll never get there." Their attention shifts toward evidence of failure. The loop weakens. What Could Have Prevented It? Focus on progress instead of perfection. Dr. Caroline Leaf would remind us that thoughts influence neurochemistry. A better question might be: "What is improving that I haven't noticed yet?" Loop Repair Look for small wins. Better sleep More energy More consistency Better habits Progress fuels dopamine. Dopamine fuels effort.   Loop Breaker #3: Distracted Attention What Happened? You sit down to work. A text arrives. Then email. Then social media. Then another interruption at your office door. Attention becomes fragmented. Learning slows. Progress slows. Reward disappears. What Could Have Prevented It? Protect your attention. John Medina taught us: Attention determines what the brain decides matters. Loop Repair Create: 30-minute focus blocks Phone-free work periods (with notifications turned off) One-task-at-a-time sessions The brain rewards completion. Not multitasking.   Loop Breaker #4: Too Much Challenge What Happened? This one surprises many people. Doing hard things strengthens the brain. But doing impossible things breaks the loop. A person starts: A new diet A new exercise plan A new business A new habit And tries to change everything at once. The challenge becomes overwhelming. What Could Have Prevented It? Start smaller. The AMCC grows when challenges are difficult but achievable. Loop Repair Ask: "What's the smallest difficult thing I can consistently repeat?" Not: "What's the hardest thing I can do today?"   Loop Breaker #5: Poor Recovery/Low Energy   What Happened? This is actually my hiking example that I've mentioned previously. Everything was working. My recovery improved. My WHOOP age improved 6.4 years younger than my actual age. My fitness improved- v02 max increased. Then I increased the challenge. Longer hikes. More strain. More effort. But not enough recovery time in between. I could actually see the reward disappearing in real time. The effort at the end of these longer hikes felt exhausting instead of energizing. I know that doing difficult things makes my brain stronger, but I was close to giving up on something I really enjoyed. What Could Have Prevented It? Recovery needed to increase alongside challenge. The mistake wasn't hiking, or making the hike more challenging. The mistake was believing: More is always better. Loop Repair Alternate: Hard days Easy days Increase recovery as strain increases. As Friederike Fabritius taught us: Performance isn't built through effort alone. It's built through effort and recovery. Once I put more attention on recovery before pushing again, the broken motivation loop repaired, and the end of those difficult hikes became energizing again (with the right amount of rest).   Loop Breaker #6: No Visible Progress What Happened? A salesperson makes: 50 calls 100 calls 150 calls No results. The brain begins asking: "Why bother?" The reward disappears. What Could Have Prevented It? Measure leading indicators instead of outcomes. Instead of focusing only on sales: Track: Calls completed Meetings booked Relationships built Skills improved Loop Repair Celebrate effort metrics. Not just outcome metrics. The brain needs evidence that effort matters. Also, if the strategy you are using is not yielding results, try a different one. Ask others who are having success, what they are doing, and how they are getting results. Once you can identify where your loop is breaking, fixing it requires doing something that you were not doing before.   The Big Lesson Every loop break in this phase points back to one question: What link failed? Was it: Meaning? Thoughts? Attention? Progress? Recovery? Challenge? Because the loop rarely breaks all at once. Usually one link weakens first. And the good news is: If you can identify the broken link, you can repair the loop. What About Doing Hard Things? One of the most fascinating concepts we explored this phase was the work surrounding the: Anterior Mid-Cingulate Cortex (AMCC) This area of the brain appears to play an important role in: Persistence Self-regulation Attention control Doing things we don't feel like doing Research suggests this area strengthens when we repeatedly choose meaningful challenges. Not impossible challenges. Not burnout. Not exhaustion. Meaningful challenges. Example Choosing: The workout you don't feel like doing. The difficult conversation you've been avoiding. The presentation that makes you nervous. The study session when you'd rather scroll your phone. Every time we choose effort over comfort, we may be strengthening the neural systems responsible for persistence and researchers also would say, the will to live. The Secret to Keeping the Loop Going After everything we've learned this phase, the answer is surprisingly simple: The loop stays alive when effort feels worthwhile. That means: ✅ Meaning ✅ Purpose ✅ Focus ✅ Progress ✅ Recovery ✅ Challenge But not too much challenge. Because challenge without recovery becomes burnout. And recovery without challenge becomes stagnation. The sweet spot lies in the middle. Instead of blaming ourselves, we can start diagnosing the system to build a stronger, more resilient version of ourselves. How to Use the "Find Your Gap" Framework Whenever you feel: Stuck Unmotivated Burned out Distracted Overwhelmed Plateaued Ask yourself: Which phase is broken? Because the problem is rarely "everything." Usually it's one phase creating a bottleneck for the others.   Phase 1 Gap: Regulation & Safety Ask: Am I sleeping well? Am I recovered? Is stress overwhelming me? Is my nervous system regulated? Signs This Is Your Gap Anxiety Exhaustion Brain fog Poor sleep Irritability Example A teacher can't focus. They assume they need more motivation. But they're sleeping 5 hours a night. The real gap isn't motivation. It's regulation. Solution Fix: Sleep Recovery Stress management First.   Phase 2 Gap: Neurochemistry & Motivation Ask: Do I still know why this matters? Am I seeing progress? Has the reward disappeared? Have I lost momentum? Signs This Is Your Gap Procrastination Lack of drive Loss of enthusiasm Feeling stuck Example This was your hiking example. You still had the ability. You still had the discipline. You simply stopped feeling rewarded by the effort. Solution Repair the Motivation Loop: Reconnect to purpose Reduce challenge temporarily Improve recovery Look for progress   Phase 3 Gap: Movement, Learning & Cognition Ask: Am I moving enough? Am I physically engaged? Am I learning new things? Is my brain being challenged? Signs This Is Your Gap Low energy Mental sluggishness Poor concentration Feeling mentally flat Example Someone spends 10 hours at a desk. Their motivation is fine. Their sleep is fine. But they're sedentary. Movement is the missing ingredient. Solution Move first. The research from Chuck Hillman and John Ratey suggests movement often improves: Attention Mood Learning Memory   Phase 4 Gap: Perception, Emotion & Social Intelligence Ask: Am I seeing this situation clearly? Am I understanding others? Do I feel connected? Signs This Is Your Gap Conflict Miscommunication Isolation Emotional reactivity Example A leader thinks: "Nobody supports my vision." But the real issue is communication. The gap isn't motivation. It's perception. Solution Improve: Listening Emotional awareness Perspective-taking Relationships   Phase 5 Gap: Integration, Insight & Meaning Ask: Does this align with who I want to become? Am I moving toward something meaningful? Do I have clarity? Signs This Is Your Gap Success without fulfillment Feeling lost Lack of direction Constantly chasing goals Example Someone has achieved everything they wanted professionally. But they still feel empty. The gap isn't performance. It's meaning. Solution Reconnect with: Values Purpose Identity Contribution to the World. The Most Powerful Question At the end of every week, ask: "Where is my gap?" Is it:

Chief Asia Economist Chetan Ahya joins Head of India Research and Chief India Equity Strategist Ridham Desai to break down India's macro outlook, capital flows and sector opportunities.Read more insights from Morgan Stanley.----- Transcript -----Chetan Ahya: Welcome to Thoughts on the Market. I'm Chetan Ahya, Morgan Stanley's Chief Asia Economist.Ridham Desai: And I'm Ridham Desai, Morgan Stanley's Head of India Research and Chief India Equity Strategist.Chetan Ahya: Today, the biggest takeaways from our India Investment Forum in Mumbai. From the shifting outlook for India's markets and flows to the sectors driving the next phase of corporate earnings and CapEx.It's Friday, June 12th at 7PM in Hong Kong.Ridham Desai: And 4:30PM in Mumbai.Chetan Ahya: Ridham, the Morgan Stanley's India Investment Forum took place in Mumbai last week, and I was there with you. These events are a great opportunity to speak with investors who come across from the globe to attend. Now that we have had a few days to process the conversations, what stood out to you? What was the biggest shift in investor sentiment that you picked on?Ridham Desai: So, Chetan, I think it's been the case of a continuing story about India. Domestic investors look that they are bullish, and foreign investors continue to stay rather cautious on the Indian markets. We could see that in the overall attendance. In contrast, I think domestic investors were looking for the next stock that they wanted to buy. They were seeking opportunities, and there was a lot of interest in meeting companies.Before we get into markets, let me turn back to you from a macro side. India's growth story remains strong, but relative growth appears to be cooling. This is in contrast to markets like Japan, Taiwan, Korea, and the US. How should investors think about India's macro positioning in that context?Chetan Ahya: So, Ridham, when I look at the macro data in India, they're all indicating a meaningful upside in the growth trend. So I'll just cite two key cyclically sensitive macro data points. One is the banking system credit growth, and number two is the auto sales, particularly the passenger vehicle. So bank credit growth is growing as of the last biweekly data point that we got. It's growing at seventeen point seven percent year-on-year, and car sales are growing at twenty-seven percent in the month of May.But as you were mentioning earlier, the relative growth opportunity is a challenge for India and to just share the numbers on the earnings growth for the first quarter that we saw across the region. So we saw Korea's earnings growth at one hundred and seventy percent. We saw Taiwan's earnings growth at forty-eight percent year on year. Japan at thirty-three percent. The US has seen a growth of about twenty-seven percent year on year.So in that context, when India is reporting thirteen percent growth, it's becoming a challenge for investors to look for opportunities in India relative to other markets. Either they are more focused on the other markets than India. So let me come back to you, Ridham. Staying with the investment implications, India projects stable valuations and strong corporate earnings, but its relative growth advantage has narrowed. How should investors reconcile this contradiction?Ridham Desai: If I go back thirty-five years, as long as we have the MSCI index series, and as far as I have been in this industry, this is the lowest relative multiple that India has traded at. And indeed, growth last year was weak. But if you see QOQ, we have started to accelerate. The broad market earnings growth trajectory has shown a doubling in the quarter that ended March over the quarter that ended December.But it underscores the point you made about the relative growth complex. It's clearly not in India's favor. And a lot of the capital in the world is short-term oriented, and it cares for what growth is gonna come in the next quarter or two. And that's the state of the market right now.However, what I would say is that equities is a quintessential long-duration asset class. In the long run, what matters is terminal growth. I don't really think India's terminal growth has moved much. It remains far superior to a lot of other countries around the world. And therefore, I think this does present itself as a great opportunity for a long-term investor while the markets are digesting this relative growth disadvantage that India seems to have over the next, say, three or four quarters.Chetan Ahya: And Ridham, another theme from the forum was policy action to attract capital. Policymakers announced a number of measures right as our conference ended and they aimed to withdraw withholding tax on debt investors, also providing banks with an incentive to take up more dollar borrowing. How central are these measures to sustaining foreign inflows into Indian markets?Ridham Desai: I think the measures taken by policymakers are very important, probably amongst the most important policy actions this year. The removal of taxation on debt investors will make a difference. The provision for hedging to external commercial borrowings as well as to foreign currency deposits will make a difference.It should boost flows into India over the next twelve months. That said, these measures may not help the equity flows because the equity flows, I think, are going to depend on the relative growth situation. Now, there's only that much India can do to lift its growth. It may accelerate to the high teens. So growth elsewhere needs to decelerate for equity investors to return. Or India needs to see the start of a major IPO cycle because in primary issuances, foreigners do come to buy, and that may change the net picture on FBI flows in the equity markets.But as far as the debt markets are concerned, I think the measures taken last week are going to prove to be quite potent, and India should see the benefits accruing over the next few weeks and months.Chetan, from your perspective, how important is the policy backdrop right now in determining whether India can keep attracting long-term global capital despite more competitive returns elsewhere in the short run?Chetan Ahya: So Ridham, I think the key focus for the policymakers had been with these measures to boost short-term capital inflows to stabilize the currency. There has been a balance of payment deficit. So from that perspective, the short-term capital inflow augmentation effort as you mentioned, has been the correct move. But from the long-term perspective, we think that the government needs to boost competitiveness of the Indian manufacturing. Because in the context in which AI could affect India's services exports, there is a need to augment more export receipts from the manufacturing sector. At the same time, if they improve the competitiveness of the manufacturing sector, it will help India to attract more capital inflows from long-term investors for the purpose of FDI.And the good news is that the government is on it. They are taking a number of measures to boost that competitiveness in the manufacturing. But we think that there is more action needed and hopefully in the intention to improve the balance of payment dynamics and exports from manufacturing sector, we will see more actions from the government in the coming months.Ridham Desai: Chetan, you've also written extensively about the structural capital spending cycle in Asia and India. Can you walk us through the key details here, especially in the Indian context?Chetan Ahya: I think the key story that we are observing, it's sort of more or less global, but definitely very clearly seen in Asia, that there seems to be a super cycle for CapEx as well as industrial activity. This CapEx cycle is effectively driven by spending in four key sectors, and that is AI and AI-related digital infrastructure, energy, defense, and industrial onshoring-related CapEx.Now, as far as India is concerned, we are seeing investments in all the four segments that I just mentioned. In fact, it's seeing a significant amount of activity in the space of energy. And, similarly, we are seeing a lot of policy measures, I mentioned earlier, in terms of boosting manufacturing competitiveness.But at the heart of it is government's effort to onshore industrial supply chain. So India's CapEx has also inflected higher. Having said that, the difference between India and, let's say, North Asia, which is Korea, Taiwan, Japan and China, is that they are also a big player in the export market for capital goods when there is global CapEx cycle upswing happening. Nevertheless, India will see the benefit of this CapEx cycle in terms of its own growth push, as well as improvement in productivity.So Ridham, how would you think about the sectoral opportunity within the Indian markets?Ridham Desai: We see a lot of interest in some of these sectors which you mentioned. But actually, I would like to start off with financials. I see the banks in a very sweet spot. Balance sheets are in pristine condition. The interest rate cycle has troughed, which means margins for the banks have also bottomed and credit growth is finally accelerating. If this CapEx cycle unfolds like the way you are describing it, I think financials will stand to gain the most.And interestingly, the valuations are quite good, both on an absolute as well as on a relative basis. Also, of course, investors can go directly into those sectors which are doing this capital spend. Energy to start with, semiconductors, fertilizers, data centers and aerospace.The only thing to note here is that not everywhere are the valuations attractive enough because in some cases the market has recognized the coming growth cycle and has started to price that in. So we have to be careful about the valuations. But I think financials and industrials are clearly great opportunities in the context of this CapEx recovery that India is likely to see in the coming five years.Chetan Ahya: And additionally, the most requested companies at the summit, Ridham, were consumer sector companies. What do you think investors are looking for at this sector over others?Ridham Desai: So, Chetan, I think from a structural perspective, the Indian consumer is quite clearly the best place to be. In fact, I would say that it's the leverage that India enjoys over the rest of the world.The one point five billion people in this country are split across, say, a hundred and fifty cohorts of ten million each, and each of these cohorts have got different consumption opportunities. So depending on what product or service you're offering to your consumers, there's a market in India, and which in nominal terms is growing between ten and fifteen percent.As we know, last year India accounted for something around seventeen or eighteen percent of global GDP growth, which means depending again on what you are selling to your consumer, India could be between ten and hundred percent of your revenue growth. So India's consumer is something that hardly anybody can avoid.So in summary, Chetan, when I look at it from an investment opportunity, financials, industrials, and consumption, not necessarily in that particular order, are probably the best places for investors to look at. However, IT services, I think could be the dark horse. It's a sector right now which is disrupted or potentially disrupted by AI, and there's a lot of confusion there.But I think as the dust settles on this, it may emerge as one of the most interesting areas for investors to look at. So there's a lot of stuff in India happening right now. I think growth is accelerating. Valuations are looking quite interesting. In fact, the best that they've been in many, many years.Trading performance suggests that investors are not positioned at all. And if things start looking up, then India could be a very good market in the coming twelve months.Chetan Ahya: Ridham, thanks for taking the time to talk.Ridham Desai: Great speaking with you, ChetanChetan Ahya: And thanks for listening. If you enjoy our Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or a colleague today.

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list: 1. RASolute 302 - daraxonrasib and its standing ovation 2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs 3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology 4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients) 5. PROTEUS - meh 6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly 7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC The Learning Oncology Companion from KelleyCPharmD: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Wells is entering a dark phase and no, not emotionally (well, maybe) and Brandi woke up with what can only be described as a broken hip. Oh, and the Aliens are coming! After Wells attended a sneak preview of Steven Spielberg's new movie, Disclosure Day, he has some THOUGHTS. Is Spielberg a government psyop slowly preparing us for alien contact? He thinks yes. Then, your favorite hosts bond over the undeniable greatness of cheese which leads them to ranking their favorites, debating the best burger cheeses and some how they end up at Doritos dipped in cottage cheese... It's not YFT without a few tangents! And, of course, they provide their thoughts on their favorite things this week, including: (12:39) Disclosure Day (Wells got a sneak peak!) (16:24) Girl on the Train (17:18) Office Romance (19:50) Cape Fear(24:28) Good Girls Guide to Murder (25:54) Famous by Blake Crouch (spoiler alert!) (33:47) Obsession DM us on Instagram and tell us your favorite cheese! Love ya, Fam! Thank you to our awesome sponsors: BetterHelp: You don't have to say yes to everything this summer. Find support in therapy. Sign up and get 10% off at BetterHelp.com/yft. First Leaf: Stop settling for wines that don't quite hit the mark. Head to TryFirstleaf.com/YFT to sign up and you'll get 50% OFF your first box PLUS free shipping for an entire year. Hers: Ready to reach your goals? Visit forhers.com/yft to get personalized, affordable care that gets you. Quince: Go to Quince.com/yft for free shipping on your order and 365-day returns. Now available in Canada, too! Skims: Shop Everyday Cotton, and all of my favorite bras and underwear at http://www.skims.com/ #skimspartnerZazzle: Right now, save 25% on your first order at Zazzle.com. Zenni: Go to zenni.com/podcast and use code PODCAST15 for off your first order. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After the events of the marriage of Lady Gwenhilt and Lord Maurice, winter comes again. In sir Queegan's absence, a new knight arrives at court. For a limited time, save 15% on all Pendragon products with code "PENCANNON3" at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://chaosium.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Watch the video here: ⁠https://youtu.be/1ZKwR7WCVS8 Access ad-free episodes, exclusive podcasts, and more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠jointhenaish.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Come see us LIVE in a city near you at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.glasscannonnetwork.com/tour⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Get the facts, without the spin. UNBIASED offers a clear, impartial recap of US news, including politics, elections, legal news, and more. Hosted by lawyer Jordan Berman, each episode provides a recap of current political events plus breakdowns of complex concepts—like constitutional rights, recent Supreme Court rulings, and new legislation—in an easy-to-understand way. No personal opinions, just the facts you need to stay informed on the daily news that matters. If you miss how journalism used to be, you're in the right place. In today's episode: DOJ Acknowledges In Court Filing Anti-Weaponization Fund Is Over. Here's What It Means For Future of Fund. (0:53) Lawsuit Filed Challenging UFC Cage on White House Lawn (5:21) EPA Takes New Step to Reduce Animal Testing (9:25) Trump's Latest Interview with NBC's 'Meet the Press.' Here's What Happened. (~15:16) Israel and Iran Exchange Fire For First Time Since April; Trump Acknowledges Heated Call with Netanyahu (~24:43) Quick Hitters (~29:29) Critical Thinking Segment (~33:35) ⁠Watch⁠ this episode on YouTube. Follow Jordan on ⁠Instagram⁠ and ⁠TikTok⁠. All sources for this episode can be found ⁠here.⁠  Only by using my link, you can get 40% off the unlimited access Vantage plan! Go to groundnews.com/up. Learn more about your ad choices. Visit podcastchoices.com/adchoices